SUBJECT INDEX

Acetyl-l-carnitine, 1393
  active avoidance behavior
  open field
  passive avoidance behavior
Acetylcholine levels, 1801
  arecholine
  norepinephrine levels
ACh levels, 1457
  amneisa
  reserpine
  syrosingopine
Active avoidance
  catecholamines, 631
  cerebral embolization, 687
  drug interactions, 631
  flinch jump threshold, 687
  memory impairment, 687
  memory retention, 631
  passive avoidance, 631, 687
  protein synthesis inhibitors, 631
Active avoidance behavior, 1393
  acetyl-l-carnitine
  open field
  passive avoidance behavior
Activity stress, 869
  drinking
  ethanol
  mortality
  ulcer development
Acute and chronic administration, 1491
  diazepam
  human studies, males
  5-hydroxytryptamine (5-HT) function
  ^{3}H-imipramine binding
  L-tryptophan
Acute vs. chronic effects, 1423
  jumping behavior
  locomotor activity
  thyrotropin-releasing hormone (TRH)
Adenosine, 9
  cortical cyclic AMP
  lithium
Adenosine analogues, 263
  ICV injections
  locomotor activity
Adenosine receptors, 429
  potentiation
  sweeteners
  taste
Adenylate cyclase, 1115
  ethanol intoxication
  genetic breeding
  motor impairment
  Na+K-ATPase
  5′-nucleotidase
Adrenal medulla, 33
  cardiac hypertrophy
  catecholamines
  ethanol
Adrenalectomy, 1651
  glucocorticoids
  hypnotic response
  hypothermia
  phenobarbital
Adrenergic receptor changes, 1587
  foot shock
  stress
β-Adrenergic receptors, 1397
  electrophysiological responsiveness
  hippocampus
  lesions, DSP4
  norepinephrine concentration
Adrenocorticotropic hormone (ACTH)
  brain lipase, 1543
  medial septum, 1253
  open field behavior, 1253
  polyamines, 1543
  self-stimulation, 1253
α-Adrenoceptor blockade, 613
  sleep
  wakefulness
β-Adrenoceptor desensitization, 991
  age differences
  plasma corticosterone
  stress
α-Adrenoceptors, 305
  dopamine receptors
  locomotor activity
  norcocaine
β-Adrenoreceptors, 177
  clenbuterol
  learned-helplessness
  salbutamol
  shuttle-box
Age differences
  β-adrenoceptor desensitization, 991
  amphetamine, 503
  illumination, 503
  methylphenidate, 503
  plasma corticosterone, 991
  response speed, 503
  squirrel monkeys, 503
  stress, 991
Aggression
  anticholinergic agents, 581
  apomorphine, 773
  asymmetry, 549
  benzodiazepine, 1645
  β-carboline, 1645
  cats, 581, 1821
  chickens, 549
  copulation, 549
  drug interactions, 1821
  glutamate, 549
  6-hydroxydopamine (6-OHDA) 773, 1821
  locus coeruleus, 773
  psychomotor stimulation, 581
  social behavior, male rats, 1645
Air blast stimulation, 1007
  anticonvulsant effects
  GABAmimetic drugs
  gerbils, epilepsy prone
  tolerance
Alcohol consumption, 271
  conflict
  food deprivation
  stress
  unavoidable shock
Alcohol deprivation, 1451
  neonatal clomipramine
  strain differences
  voluntary alcohol consumption
Alcohol preference, 879
  emotional reactivity
  strain differences
Alternation, 1353
  lesions, basal forebrain
  memory
  scopolamine
  spatial discrimination
Amino acid transport, 143
  blood-brain
  long term consequences
  protein metabolism
Aminophylline
  amygdala, 1599
  dentate gyrus, 85
  inhibition, 1599
  kindling, 85, 1599
  perforant path stimulation, 85
  seizures, 1599
Amnesia, 1457
  ACH levels
  reserpine
  syrosingopine
Amphetamine
  age differences, 503
  anorexia, amphetamine induced, 1047
  anti-conflict action, 241
  benzodiazepines, 241
  calcitonin, 1203
  cathinone, 205
  caudate nucleus, 1739
  chlordiazepoxide, 241
  classical conditioning, 883
  cocaine, 205, 1793
  conditioned drug effects, 883
  conditioned taste avoidance, 883
  discrimination, 211
  drug differences, 1739
  drug discrimination, 205
  drug sensitivity, 1793
  dyskinesia, 1203
  housing conditions, 1793
  illumination, 503
  juvenile rats, 455
  lead, 211
  learning, 1617
  lesions, hypothalamus, 1047
  lithium, 883
  locomotor activity, 455, 1203, 1739
  medial prefrontal cortex, 1617
  methylphenidate, 503
  morphine, 1739
  nicotine, 883
  overtraining reversal effect, 1539
  play behavior, 455
  place preference, 1793

response speed, 503
reversal learning, 1539
seizures, 1617
self-stimulation, 1617
septal nucleus, 1739
squirrel monkeys, 503
stereotyped behavior, 1329
strain differences, 1329
d-Amphetamine
cocaine, 765
drug discrimination, 765, 1305, 1665
drug interactions, 1305
ethanol, 1305
grooming, 1025
human studies, 1665
mazindol, 1665
monkeys, 765
pentobarbital, 1305
phenylpropanolamine, 1665
pigeons, 1305
proximity, 1025
route of administration, 765
social behavior, 1025
stumptail macaques, 1025
subjective effects, 1665
Amphetamine, fixed interval, 757
monoamines
morphine, fixed interval
prenatal morphine
Amygdala, 1599
aminophylline
inhibition
kindling
seizures
Amygdaloid complex, 1561
chronic administration
clozapine
haloperidol
Analgesia
antinociception, 791
diazepam, 319
foot shock, 791
formalin test, 319
humoral mediation, 791
morphine, 319
stress, 319
Analgesia, stress induced, 829
cold-restraint stress
methylnalorphinium
Analgesic action, 1247
opioids
quantitative differences
Androgens, 285
R1881
sexual orientation
Angiotensin II
arterial pressure, 1573
atrial natriuretic factor (ANF), 1573
drinking, 721, 1573
drug interactions, 721
heart rate, 1573
hypertonic saline, 721
isoproterenol, 721
quinpirole, 721
Animal hypnosis, 1623
chickens
serotonin
tonic immobility
Animal models
anxiety, 1479
ascorbic acid, 781
catalepsy, 781
drinking fluid with ethanol, 625
drug interactions, 781
Fetal Alcohol Syndrome, 625
haloperidol, 781
5-hydroxytryptamine (5-HT), 1479
pregnancy, 625
Aniracetam, 1123
Hydergine®
hypoxia
passive avoidance
scopolamine
vincamine
vinpocetine
Anorexia, amphetamine induced, 1047
amphetamine
lesions, hypothalamus
Antianxiety agents, 237
anticonflict
apomorphine
central dopamine autoreceptors
Anticholinergic agents, 581
aggression
cats
psychomotor stimulation
Anticholinergic sensitivity, 865
drug tolerance
exercising, chronic
muscarinic antagonists
Anticholinergics, 135
antidepressants
muricide
Anticonflict, 237
antianxiety agents
apomorphine
central dopamine autoreceptors
Anti-conflict action
amphetamine, 241
benzodiazepines, 241, 1057
chlordiazepoxide, 241
consummatory contrast, 1057
midazolam, 1057
Anticonvulsant drugs, 1583
pigeons
repeated acquisition procedure
tolerance
Anticonvulsant effects, 1007
air blast stimulation
GABAmimetic drugs
gerbils, epilepsy prone
tolerance
Anticonvulsive effects, 555
automaintenance
negative automaintenance
pigeons
Antidepressants
anticholinergics, 135
desipramine, 155
locomotor activity, 1361
morphine analgesia, 155
muricide, 135
opioid receptors, 155
stress, chronic, 1361
Antiepileptic drugs, 1383
prenatal drug exposure
seizure susceptibility
Antihistaminic drugs, 925
antinociception
drug differences
drug interactions
Anti-inflammatory drug binders, 1031
human serum albumin
indomethacin
indoprofen
Antinoception
analgesia, 791
antihistaminic drugs, 925
p-chloroamphetamine, 709
cholinergic-opiate interactions, 733
diisopropylfluorophosphate (DFP), 733
dopamine agonists, 425
dopamine antagonists, 425
drug differences, 925
drug interactions, 925
foot shock, 791
formalin test, 709
hot plate, 425, 709
humoral mediation, 791
lesions, ascending serotonergic pathways, 709
neurotensin, 425
tail flick, 709
Antipsychotic drugs, 1409
dopaminergic neurotransmission
extrapyramidal motor effects
locomotor activity
Anxiety
animal models, 1479
anxiogenic drug effects, 525
anxiolytic activity, 1471
anxiolytic drug effects, 525
benzodiazepines, 1471
buspirone, 701
conflict, 701
exploratory activity, 525
gepirone, 701
hippocampus, 1733
5-hydroxytryptamine (5-HT), 1467, 1479
indole-aldehyde adduct, 1733
lesions, 5,7-dihydroxytryptamine (5,7-DHT), 701
open field behavior, 1733
serotonergic function, 1467
serotonergic mechanisms, 701
serotonergic neurons, 1471
tetrahydro-β-carboline, 1733
waiting capacities, 1471
Anxiogenic drug effects, 525
anxiety
anxiolytic drug effects
exploratory activity
Anxiolytic activity, 1471
anxiety
benzodiazepines
serotonergic neurons
waiting capacities
Anxiolytic drug effects, 525
anxiety
anxiogenic drug effects
exploratory activity
Anxiolytic responding, 855
Ro 15-1788
rhesus monkeys
self-administration
Apomorphine
aggression, 773
antianxiety agents, 237
anticonflict, 237
autoreceptors, 291
central dopamine autoreceptors, 237
dopamine receptors, 1593, 1639
drug-opiate interaction, 1779
grooming, 1779
haloperidol, 1593

6-hydroxydopamine (6-OHDA), 773
hypomotility, 1639
hypothyroidism, 1593
locomotor activity, 291, 1593
locus coeruleus, 773
multivariate statistics, 291
naloxone, 1779
neuroleptics, atypical, 1639
opiates, 1779
stereotyped behaviors, 1639
stretching, 1779
yawning, 1779
Apparatus
activity box, 1755
elevated plus-maze, 525
osmotic minipumps, 1007
push-pull cannula, 147
shuttle box, 1789
treadmill, 1805
Arecoline, 1801
acetylcholine levels
norepinephrine levels
Arterial pressure, 1573
angiotensin II
atrial natriuretic factor (ANF)
drinking
heart rate
Ascorbic acid, 781
animal models
catalepsy
drug interactions
haloperidol
L-Ascorbic acid, 543
ethanol-induced CNS depression
ethanol-induced hypnosis
motor coordination
Asymmetry, 549
aggression
chickens
copulation
glutamate
Atrial natriuretic factor (ANF), 1573
angiotensin II
arterial pressure
drinking
heart rate
Atropine
behavioral tolerance, 845
caudate-putamen, 905
drug interactions, 845
human studies, 1111
learning and retention, 905
negative reinforcer, 905
organophosphates, 845
passive avoidance, 905
performance assessment battery, 1111
psychometrics, 1111
retrograde amnesia, 905
soman, 845
Automaintenance, 555
anticonvulsive effects
negative automaintenance
pigeons
Autonomic changes, 329
calcium antagonist
cats
Autoreceptors, 291
apomorphine
locomotor activity
multivariate statistics
Auto-shaping, 715
cholinergic activity
positively-reinforced learning
striatum
Aversion, 5
calcitonin gene-related peptide (CGRP)
satiety
Avoidance, 199
fluoxetine
olfactory bulbectomy
Y-maze
zimeldine

Backwards walking, 861
bremazocine
opioid kappa receptors
psychotomimetic activity
Baclofen, 1301
drug interactions
in vivo
neurotoxicity
phenytoin
progabide
seizures
Barbital, 801
cross-tolerance
ethanol
pentobarbital
tolerance
Barbiturates, 727
convulsant barbiturates
locomotor activity
BAT thermogenesis, 605
body weight
drinking
eating
phenylpropanolamine
Behavioral effects
brain levels, amino acids, 1323
brain levels, transmitter amines, 1323
dietary histidine loading, 1323
dietary methionine loading, 1323
dorsal raphe nucleus, 1487
drug interactions, 341
hormone levels, 1749
human studies, males, 1749
lysergic acid diethylamide-25 (LSD-25), 341
marijuana, 1749
methyl-β-carboline-3-carboxylate (β-CCM), 1487
microinjections, 1487
neurochemical effects, 341
portacaval shunt, 1323
subjective effects, 1749
Behavioral inhibition, 1497
benzodiazepines
differential reinforcement of low rates of response
melatonin
Behavioral pathogenesis, 165
dysmorphogenesis
Fetal Alcohol Syndrome
pregnancy
Behavioral recovery time, 1287
ibotenic acid
lesions, nucleus basalis
Behavioral thermoregulation, 1147
preferred ambient temperature
sodium pentobarbital
temperature gradient
Behavioral tolerance, 845
atropine
drug interactions
organophosphates
soman
Benzodiazepine antagonists
benzodiazepine receptors, 1263
chlordiazepoxide, 999
diazepam, 963
drug discrimination, 999
drug interactions, 963, 999
intracranial self-stimulation, 193
monkey/pigeon comparisons, 963
pentobarbital, 999
righting response, 963
Ro 5-4864, 193
ultrasonic isolation calls, 1263
Benzodiazepine binding sites, 1
GABA agonist
kidneys, mice
Benzodiazepine-receptor ligands, 841
β-carboline
convulsions
flurazepam
Benzodiazepine receptors
benzodiazepine antagonists, 1263
inosine, 121
pigeons, 121
punished behavior, 121
ultrasonic isolation calls, 1263
Benzodiazepines
aggression, 1645
amphetamine, 241
anti-conflict action, 241
anxiety, 1471
anxiolytic activity, 1471
behavioral inhibition, 1497
β-carboline, 1645
CGS 8216, 1703
chlordiazepoxide, 1057
consummatory contrast, 1057
differential reinforcement of low rates of response, 1497
melatonin, 1497
midazolam, 1057
route of administration, 1703
serotonergic neurons, 1471
social behavior, male rats, 1645
waiting capacities, 1471
Bin analysis, 1679
DHT model
locomotor activity
motor habituation
Blood-brain, 143
amino acid transport
long term consequences
protein metabolism
Body temperature, 1761
opioid effects
route of administration
Body weight
BAT thermogenesis, 605
drinking, 605
eating, 605
food intake, 1817
phenylpropanolamine, 605
pituitary-thyrotropin-releasing-hormone (TRH), 1817
Brain
amygdala, 115, 1561, 1599, 1715
basal forebrain, 1353
brainstem, 445, 1587
caudate nucleus, 1739
caudate putamen, 715, 905, 1189

cerebellum, 127
cerebral cortex, 1377, 1673
cerebral ventricle, 581
corpus striatum, 1829
cortex, 1587, 1801
dentate gyrus, 85
dorsal raphe nucleus, 359, 919, 1487
dorsomedial nuclei, 299
facial nucleus, 359
forebrain, 445
frontal cortex, 299
hippocampus, 107, 183, 519, 777, 1141, 1377, 1397, 1403, 1673, 1729, 1733
hypothalamic arcuate nucleus, 1343
hypothalamic paraventricular nuclei, 299, 931
hypothalamus, 115, 193, 229, 513, 1047, 1175, 1587, 1715
inferior central nucleus, 347
lateral hypothalamus, 919
lateral septal nuclei, 673
lateral septum, 107
limbic forebrain, 365
locus coeruleus, 115, 773
medial entorhinal cortex, 439
medial hypothalamus, 497
medial prefrontal cortex, 1429, 1617
medial preoptic area, 1015, 1065
medial septum, 107, 1253, 1263
median eminence, 299
mediodorsal hypothalamus, 575
mesencephalic central gray, 497
mesencephalon, 773
mesocortex, 365
mesolimbus, 365
mesostriatum, 365
midbrain, 513
nucleus accumbens, 61, 223, 365, 1185, 1189, 1263, 1829
nucleus basalis, 1287
nucleus basalis magnocellularis, 1353
nucleus raphe dorsalis, 1189
occipital cortex, 1729
paraventricular nucleus, 911
pituitary, 1673
pons medulla, 1377
prefrontal cortex, 1829
raphe obscurus, 1263
septal nucleus, 1739
septal region, 107
septum, 1635
striatum, 223, 715, 773, 795, 809, 941, 983, 1141, 1189, 1703
subcortex, 1801
thalamus, 813
ventral tegmentum, 919, 1101
ventromedial hypothalamic nucleus, 299
ventromedial hypothalamus, 673
visual cortex, 71

Brain catecholamines, 1715
desipramine
muricide
olfactory bulbectomy

Brain histamine regulation, 513
diazepam
stress

Brain levels, amino acids, 1323
behavioral effects
brain levels, transmitter amines
dietary histidine loading
dietary methionine loading
portacaval shunt

Brain levels, transmitter amines, 1323
behavioral effects
brain levels, amino acids
dietary histidine loading
dietary methionine loading
portacaval shunt

Brain lipase, 1543
adrenocorticotropic hormone (ACTH)
polyamines

Brain self-stimulation, 439
naloxone
nose-poke
opioid-receptor blockade

Brain serotonin metabolism, 1611
learning/memory tests
open field
portacaval shunt
somatosensory reactivity

Brain stimulation reward
D_1 receptor, 919
D_2 receptor, 919
dopamine receptor blockade, 919
incentive contrasts, 1577
pimozide, 1577
self-stimulation, 919

Brain water content, 785
central venous pressure
fentanyl
intracranial pressure
lesions, parieto-occipital cortex
rabbits
systolic arterial pressure

Bremazocine, 861
backwards walking
opioid kappa receptors
psychomimetic activity

Brown adipose tissue (BAT), 1605
eating
nicotine
thermogenesis

Bupropion, 795
dihydroxyphenylacetic acid (DOPAC)
dopamine
locomotor activity
striatal concentrations

Buspirone
anxiety, 701
conflict, 701
dopamine, 751
gepirone, 701
lesions, 5,7-dihydroxytryptamine (5,7-DHT), 701
pigeons, 751
punished behavior, 751
serotonergic mechanisms, 701

Ca^{++} uptake, 1659
calmodulin
ethanol
synaptosomal membranes

Caerulein, 469
dopamine$_2$-receptors
exploration
serotonin$_2$-receptors

Caffeine
developmental reflexes, 1695
5,7-dihydroxytryptamine (5,7-DHT), 1039
food deprivation, 1555
6-hydroxydopamine (6-OHDA), 1039
locomotor activity, 1039, 1695
monoamine levels, 1039
postnatal exposure, lactation, 1695
sex differences, 1555
taste preference, 1695
two-bottle preference, 1555

Calcitonin, 1203
amphetamine
dyskinesia
locomotor activity

Calcitonin gene-related peptide (CGRP), 5
aversion
satiety

Calcium
depression, 445
ethanol, 949
learned helplessness, 445
neuronal sensitivity, 949
selective breeding, 949
serotonin metabolism, 445

Calcium antagonist, 329
autonomic changes
cats

Calcium antagonist binding, 417
dihydropyridine
nitrendipine
phencyclidine (PCP)

Calmodulin, 1659
Ca^{++} uptake
ethanol
synaptosomal membranes

Cannula, 1809
construction
implantation
multiple microinjections

β-Carboline
aggression, 1645
benzodiazepine-receptor ligands, 841
benzodiazepines, 1645
convulsions, 841
flurazepam, 841
social behavior, male rats, 1645

β-Carboline carboxylic acid ethyl ester (β-CCE), 823
convulsions, drug-induced
diazepam
sodium valproate

Cardiac hypertrophy, 33
adrenal medulla
catecholamines
ethanol

Catalepsy
animal models, 781
ascorbic acid, 781
drug interactions, 781
haloperidol, 781, 1785
MSH-release inhibiting factor-1 (MIF-1), 1785
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 1785

Catechol-O-methyltransferase, 1141
gerbils
β-phenylethylamine
red blood cell enzymes

Catecholamine mechanisms, 571
drug interactions
L-histidine
locomotor activity
methamphetamine

Catecholamine metabolism, 229
norepinephrine metabolism
water imbalance

Catecholamine release, 575
feeding-related changes
locomotor activity
Catecholamine terminals, 1101
intrinsic neurons
neonatal dopamine depletion
self-stimulation
ventral tegmentum
Catecholamines
active avoidance, 631
adrenal medulla, 33
cardiac hypertrophy, 33
diet-induced obesity, 299
dopamine turnover, 299
drug interactions, 631
electrocortical activity, 99
ethanol, 33
memory retention, 631
nicotine, 99
norepinephrine metabolism, 299
passive avoidance, 631
protein synthesis inhibitors, 631
Catecholaminergic pathways, 1441
6-hydroxydopamine (6-OHDA)
nociception
spinal cord
Cathinone
amphetamine, 205
cocaine, 205
drug discrimination, 205, 1161
isomers, 1161
stimulus properties, 1161
Cats
aggression, 581, 1821
anticholinergic agents, 581
autonomic changes, 329
calcium antagonist, 329
dorsal root potentials, 347
drug interactions, 351, 1821
hallucinogens, 347, 351
6-hydroxydopamine (6-OHDA), 1821
psychomotor stimulation, 581
raphe unit activity, 351
serotonin receptors, 351
Caudate nucleus, 1739
amphetamine
drug differences
locomotor activity
morphine
septal nucleus
Caudate-putamen, 905
atropine
learning and retention
negative reinforcer
passive avoidance
retrograde amnesia
Central aminergic mechanisms, 1509
convulsions, nicotine induced
nicotinic receptors
Central cholinergic system, 519
ethanol
memory dysfunction
spontaneous alternation
Central dopamine autoreceptors, 237
antianxiety agents
anticonflict
apomorphine
Central nervous system (CNS), 1203
drug discrimination
serotonergic mediation
tetrahydro-β-carboline (THBC)
Central venous pressure, 785
brain water content
fentanyl
intracranial pressure
lesions, parieto-occipital cortex
rabbits
systolic arterial pressure
Cerebral amino acids, 1315
feeding behavior
hyperosmotic environment
toads
Cerebral embolization
active avoidance, 687
choline acetyltransferase, 1729
flinch jump threshold, 687
memory, 1729
memory impairment, 687
passive avoidance, 687, 1729
CGS 8216, 1703
benzodiazepines
route of administration
ChE inhibition, 941
diisopropylphosphorofluoridate (DFP)
locomotor activity
soman
sarin
Chickens
aggression, 549
animal hypnosis, 1623
asymmetry, 549
copulation, 549
eating, 39
glutamate, 549
5-hydroxytryptamine (5-HT), 39
methoxamine, 39
serotonin, 1623
tonic immobility, 1623
Chlordiazepoxide
amphetamine, 241
anti-conflict action, 241
benzodiazepine antagonists, 999
benzodiazepines, 241
drug comparisons, 895
drug discrimination, 999
drug interactions, 999
ethanol, 93, 895
ingestion, 217
narcotic reactions, 895
palatability, 217
pentobarbital, 93, 999
phenobarbital, 895
selective breeding, 895
sleep time, 895
thiopental, 895
tolerance, 93
p-Chloroamphetamine
antinociception, 709
enantiomers, 281
fluoxetine, 281
formalin test, 709
hot plate, 709
lesions, ascending serotonergic pathways, 709
serotinin uptake, 281
tail flick, 709
N-[2-Chloroethyl]-N-ethyl-2-bromobenzyl-amine (DSP4), 777
hippocampal kindling
limbic seizures
noradrenaline depletion
wet dog shakes
Choice paradigm, 507
β-endorphin
opioids
sociosexual proclivity
Cholecystokinin octapeptide (CCK-8), 983
circling behavior
clozapine
drug comparisons
haloperidol
Choline acetyltransferase, 1729
cerebral embolization
memory
passive avoidance
Cholinergic activity, 715
auto-shaping
positively-reinforced learning
striatum
Cholinergic influences, 1157
play fighting
social development
Cholinergic-opiate interactions, 733
antinociception
diisopropylfluorophosphate (DFP)
Cholinesterase inhibition, 737
conditional taste aversion
organophosphates
Chronic administration
amygdaloid complex, 1561
clozapine, 1561
functional tolerance, 1805
haloperidol, 1561
motor coordination, 1805
phenobarbital, 1805
Chronic pain, 49
Freund's adjuvant
inflammation
nociception
Chronic spinal dogs, 393
hallucinogens
tolerance
tryptaminergic pathways
Cigarette smoke yields, 587
human studies
inhalation volumes
smoke absorption
Cigarette smoking, 159
nausea
pituitary hormone release
Cigarettes, 171
deprivation
human studies
nicotine
reinforcement
Cimetidine, 1257
footshock-induced analgesia
H_2-receptor
Circling behavior, 983
cholecystokinin octapeptide (CCK-8)
clozapine
drug comparisons
haloperidol
Classical conditioning
amphetamine, 883
conditioned drug effects, 883
conditioned taste avoidance, 883
heart rate, 677
lithium, 883
lysergic acid diethylamide (LSD), 677, 1293
nicotine, 883
nictitating membrane response, 1293
orienting reflex, 677
pizotifen (BC-105), 677
rabbits, 677, 1293

xylamidine, 677
Clenbuterol, 177
β-adrenoreceptors
learned-helplessness
salbutamol
shuttle-box
Climbing, 139
estradiol
Clonidine, 1567
eating
food competition
monkeys
Clozapine
amygdaloid complex, 1561
cholecystokinin octapeptide (CCK-8), 983
chronic administration, 1561
circling behavior, 983
drug comparisons, 983
haloperidol, 983, 1561
Cocaine
amphetamine, 205, 1793
d-amphetamine, 765
cathinone, 205
dopamine receptors, 531
drug discrimination, 205, 765
drug sensitivity, 1793
housing conditions, 1793
intracranial self-administration, 1429
medial prefrontal cortex, 1429
monkeys, 765
neuronal systems, 1429
piribedil, 531
place preference, 1793
rhesus monkeys, 531
route of administration, 765
self-administration, 531
Cocaine-caffeine interaction, 761
dose-dependent effects
locomotor stimulant activity
potentiation
Cold-restraint stress, 829
analgesia, stress induced
methylnalorphinium
Color tracking procedure, 597
drug interactions
morphine discrimination
pigeons
Conscious animals, 147
push-pull cannula
Consummatory contrast, 1057
anti-conflict action
benzodiazepines
midazolam
Conditioned avoidance, 67
lergotrile
prolactin
Conditioned avoidance response, 433
drug interactions
head shaking
luteinizing hormone-releasing hormone (LHRH)
spontaneous motor activity
Conditioned drug effects, 883
amphetamine
classical conditioning
conditioned taste avoidance
lithium
nicotine
Conditioned place aversion, 1369
ethanol self-administration
reinforcement
Conditioned taste aversion
cholinesterase inhibition, 737
drinking, 1527
drinking suppression, 463
ethanol, 463
hamsters, 567
lesions, visual cortex, 71
morphine, 71
nicotine, 567
organophosphates, 737
pimozide, 1527
place conditioning, 71
saccharin, 567, 1527
zimeldine, 463
Conditioned taste avoidance, 883
amphetamine
classical conditioning
conditioned drug effects
lithium
nicotine
Conflict
alcohol consumption, 271
anxiety, 701
buspirone, 701
food deprivation, 271
gepirone, 701
lesions, 5,7-dihydroxytryptamine (5,7-DHT), 701
serotonergic mechanisms, 701
stress, 271
unavoidable shock, 271
Construction, 1809
cannula
implantation
multiple microinjections
Convulsant barbiturates, 727
barbiturates
locomotor activity
Convulsions
benzodiazepine-receptor ligands, 841
β-carboline, 841
EEG discharges, 1241
flurazepam, 841
morphine, 1241
naloxone, 1241
penicillin, 1241
rabbits, 1241
Convulsions, drug-induced, 823
β-carboline carboxylic acid ethyl ester (β-CCE)
diazepam
sodium valproate
Convulsions, nicotine induced, 1509
central aminergic mechanisms
nicotinic receptors
Convulsions, post-decapitation, 1445
isofloxythepin
prolactin secretion
zotepine
Copulation, 549
aggression
asymmetry
chickens
glutamate
Cortical cyclic AMP, 9
adenosine
lithium
Corticosterone, 911
diurnal rhythm
eating
morphine
Cross-tolerance
barbital, 801
ethanol, 801
pentobarbital, 801
spinal reflex, 1083
tail flick, 1083
tolerance, 801
tolerance, learned, 1083
tolerance, pharmacologically-induced, 1083
Cyclazocine, 479
drug discrimination
drug history
morphine
pigeons
Cysteamine, 1707
dopamine-mediated behavior
locomotor activity
somatostatin
stereotypy
striatum

D_1 receptor, 919
brain stimulation reward
D_2 receptor
dopamine receptor blockade
self-stimulaton
D_2 receptor
brain stimulation reward, 919
D_1 receptor, 919
dopamine receptor blockade, 919
lesions, N-methyl-D-aspartate, 1829
lesions, prefrontal cortex, 1829
locomotor activity, 1829
self-stimulation, 919
stereotypy, 1829
Delta sleep-inducing peptide (DSIP)
sleep factors, 889
spontaneous hypertensive rats, 1797
stress, 1797
structure-activity relationship, 889
Dentate gyrus, 85
aminophylline
kindling
perforant path stimulation
Dependence, 27
dermorphine
tail-flick test
withdrawal
Depolarization-dependent calcium levels, 1137
ethanol sensitivity
strain differences
Depression, 445
calcium
learned helplessness
serotonin metabolism
Deprivation, 171
cigarettes
human studies
nicotine
reinforcement
Dermorphine, 27
dependence
tail-flick test
withdrawal
Desipramine
antidepressants, 155
brain catecholamines, 1715
morphine analgesia, 155
muricide, 1715
olfactory bulbectomy, 1715

opioid receptors, 155
Development, 1377
locomotor activity
prenatal stress
serotonergic neurons
Developmental reflexes, 1695
caffeine
locomotor activity
postnatal exposure, lactation
taste preference
Dextrofenfluramine, 647
locomotor activity
respiration quotient
total energy expenditure
DHT model, 1679
bin analysis
locomotor activity
motor habituation
Diallel cross, 743
genetic analysis
nicotine
open field
Diazepam
acute and chronic administration, 1491
analgesia, 319
benzodiazepine antagonists, 963
brain histamine regulation, 513
β-carboline carboxylic acid ethyl ester (β-CCE), 823
convulsions, drug-induced, 823
dogs, 1071
drug interactions, 963, 1071
fixed interval/fixed ratio schedule, 1071
formalin test, 319
human studies, males, 1491
5-hydroxytryptamine (5-HT) function, 1491
^{3}H-imipramine binding, 1491
monkey/pigeon comparisons, 963
morphine, 319
pentobarbital, 1071
perseveration, 323
response invigoration, 323
righting response, 963
sodium valproate, 823
stress, 319, 323, 513
swim task, 323
L-tryptophan, 1491
Diet-induced obesity, 299
catacholamines
dopamine turnover
norepinephrine metabolism
Dietary fat, 1775
open field
pain threshold
thermoregulation
Dietary histidine loading, 1323
behavioral effects
brain levels, amino acids
brain levels, transmitter amines
dietary methionine loading
portacaval shunt
Dietary methionine loading, 1323
behavioral effects
brain levels, amino acids
brain levels, transmitter amines
dietary histidine loading
portacaval shunt
Dietary salt-loading, 1825
drinking
ethanol selection
thirst
Differential effects, 1513
5-HT syndrome
5-HT$_{1A}$ selective drugs
Dehydration, 1129
dogs
drinking
naloxone
vasopressin levels
Differential reinforcement of low rates of response, 1497
behavioral inhibition
benzodiazepines
melatonin
Dihydropyridine, 417
calcium antagonist binding
nitrendipine
phencyclidine (PCP)
Dihydroxyphenylacetic acid (DOPAC), 795
bupropion
dopamine
locomotor activity
striatal concentrations
5,7-Dihydroxytryptamine (5,7-DHT)
caffeine, 1039
ethanol tolerance, 955
6-hydroxydopamine (6-OHDA), 1039
locomotor activity, 1039
monoamine levels, 1039
serotonergic system, 955
Diisopropylfluorophosphate (DFP)
antinoception, 733
cholinergic-opiate interactions, 733
hypothermia, 1077
locomotor activity, 1077
strain differences, 1077
Diisopropylphosphorofluoridate (DFP), 941
ChE inhibition
locomotor activity
soman
sarin
N,N-Dimethyltryptamine (DMT), 401
fixed ratio schedule
lysergic acid diethylamide (LSD)
opioid-hallucinogen interactions
Discrimination
amphetamine, 211
lead, 211
stimulus generalization, 43
1-(3-trifluoromethylphenyl)piperazine (TFMPP), 43
Diuresis, 1503
drinking
natriuresis
sodium appetite
vanadate
Diurnal rhythm, 911
corticosterone
eating
morphine
Dogs
dehydration, 1129
diazepam, 1071
drinking, 1129
drug interactions, 1071
fixed interval/fixed ratio schedule, 1071
naloxone, 1129
pentobarbital, 1071
vasopressin levels, 1129
Dopamine
bupropion, 795
buspirone, 751
dihydroxyphenylacetic acid (DOPAC), 795
feeding response, 1189
locomotor activity, 223, 795
muscimol, 1189
nucleus accumbens, 223, 1189
nucleus raphe dorsalis, 1189
pigeons, 751
punished behavior, 751
striatal concentrations, 795
striatum, 223
Dopamine agonists
antinociception, 425
dopamine antagonists, 425, 837
eating, 1195
grooming, 837
hot plate, 425
neurotensin, 425, 1195
Dopamine antagonists
antinociception, 425
dopamine agonists, 425, 837
grooming, 837
hot plate, 425
neurotensin, 425
Dopamine-mediated behavior, 1703
cysteamine
locomotor activity
somatostatin
stereotypy
striatum
Dopamine neurotransmission, 1185
grooming
lesions, nucleus accumbens
oxytocin
Dopamine receptor blockade, 919
brain stimulation reward
D_1 receptor
D_2 receptor
self-stimulation
Dopamine receptors
α-adrenoceptors, 305
apomorphine, 1593, 1639
cocaine, 531
haloperidol, 1593
hypomotility, 1639
hypothyroidism, 1593
locomotor activity, 305, 1593
neuroleptics, atypical, 1639
norcocaine, 305
piribedil, 531
REM sleep deprivation, 809
rhesus monkeys, 531
self-administration, 531
^{3}H-spiroperidol binding, 809
stereotyped behaviors, 1639
striatum, 809
Dopamine$_2$-receptors, 469
caerulein
exploration
serotonin$_2$-receptors
Dopamine release, drug induced, 1755
intracerebral dialysis
locomotor activity
stereotyped behavior
Dopamine turnover
catecholamines, 299
diet-induced obesity, 299
5-HT turnover, 79
hypothermia, 79
norepinephrine metabolism, 299
stress, 79

Dopaminergic agents, 693
  eye tracking
  methamphetamine
  monkeys
Dopaminergic function, 449
  locomotor activity
  multiple amphetamine schedule
  perinatal undernutrition
  stereotypy
Dopaminergic neurotransmission, 1409
  antipsychotic drugs
  extrapyramidal motor effects
  locomotor activity
Dorsal raphe nucleus, 1487
  behavioral effects
  methyl-β-carboline-3-carboxylate (β-CCM)
  microinjections
Dorsal root potentials, 347
  cats
  hallucinogens
Dose-dependent effects, 761
  cocaine-caffeine interaction
  locomotor stimulant activity
  potentiation
Dose response, 247
  drinking
  eating
  route of administration
Dose-response relationship
  drug discrimination, 769, 1533
  duality of effect, 1533
  ethanol, 769
  3,4-methylenedioxymethamphetamine (MDMA), 1533
  nicotine, 769
Drinking
  activity stress, 869
  angiotensin II, 721, 1573
  arterial pressure, 1573
  atrial natriuretic factor (ANF), 1573
  BAT thermogenesis, 605
  body weight, 605
  conditioned taste aversion, 1527
  dehydration, 1129
  dietary salt-loading, 1825
  diuresis, 1503
  dogs, 1129
  dose response, 247
  drug interactions, 721
  eating, 491, 605
  ethanol, 491, 869, 1825
  ethanol preference, 1089
  genetic differences, 1089
  heart rate, 1573
  hypertonic saline, 721
  isoproterenol, 721
  monkeys, 491
  mortality, 869
  naloxone, 1129
  natriuresis, 1503
  opioids, 833
  oral sensory function, 833
  phenylpropanolamine, 605
  pimozide, 1527
  quinpirole, 721
  route of administration, 247
  saccharin, 1527
  satietin, 247
  sodium appetite, 1503
  stress, 491
  taste preference, 833
  thirst, 1825
  ulcer development, 869
  vanadate, 1503
  vasopressin levels, 1129
  voluntary alcohol consumption, 1451
Drinking fluid with ethanol, 625
  animal models
  Fetal Alcohol Syndrome
  pregnancy
Drinking suppression, 463
  conditioned taste aversion
  ethanol
  zimeldine
Drug
  γ-acetylenic GABA, 1007
  acetyl-l-carnitine, 1393
  adenosine, 1599
  alcohol, 165, 879, 1451
  L-allylglycine, 497
  allylisopropylacetamide (AIA), 1219
  N-allynormetazocine (SKF 10,047), 1629
  d-N-allylnormetazocine, 1761
  l-N-allylnormetazocine, 1761
  alpha-methyl-p-tyrosine, 631
  γ-aminobutyric acid (GABA), 657, 673, 1065
  2-amino-6,7-dihydroxyaminotetraline (ADTN), 253
  6-aminonicotinamide, 785
  aminooxyacetic acid (AOAA), 1007
  aminophylline, 85, 1599
  amitriptyline, 135, 1361
  amphetamine, 61, 205, 211, 241, 449, 455, 597, 757, 837, 883, 1047, 1203, 1329, 1539, 1561, 1617, 1739, 1755, 1775, 1793
  d-amphetamine, 351, 425, 503, 765, 1025, 1305, 1429, 1665
  d-amphetamine sulfate, 963
  anileridine, 1247
  aniracetam, 1123
  anisomycin, 631
  antazoline, 1509, 1821
  apomorphine, 139, 211, 237, 291, 351, 425, 693, 751, 773, 837, 1423, 1533, 1593, 1639, 1779
  arecoline, 1157, 1801
  ascorbic acid, 781
  L-ascorbic acid, 543
  atropine, 581, 865, 905, 1509, 1821
  atropine sulfate, 845, 1111
  baclofen, 1301
  barbital, 801
  3,4-benzodiazepine tofisopam, 525
  bicuculline, 841
  bicuculline methiodide, 1065
  biperiden, 581
  bremazocine, 861
  bromocriptine, 1195
  bupropion, 135, 795
  buspirone, 525, 701, 751, 1471, 1479, 1513
  caerulein, 469
  caffeine, 211, 263, 429, 761, 1039, 1281, 1333, 1555, 1605, 1695
  calcium, 445, 949
  β-carboline carboxylic acid ethyl ester (β-CCE), 823
  cathinone, 205, 1161, 1533
  CGS-8216, 525, 999, 1071, 1703
  CGS-9896, 1703
  chlorcyclizine, 925
  chlordiazepine, 241
  chlordiazepoxide, 93, 193, 217, 895, 999, 1467, 1471, 1479, 1497
  chlorimipramine, 1361
  p-chloroamphetamine, 281, 351, 709, 1275
  N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4), 777, 1397
  p-chlorophenylalanine (PCPA), 1175
  chlorpheniramine, 925
  chlorpromazine, 351, 425, 1509, 1821
  cimetidine, 1257
  cinanserin, 537, 1057
  CL 218,872, 525
  clobazam, 1471
  clomipramine, 1451
  clonazepam, 555, 1383, 1583
  clonidine, 1083, 1567
  clozapine, 983, 1561, 1639
  cocaine, 205, 531, 597, 761, 765, 1429, 1793
  codeine, 1247
  coenzyme Q_{10}, 315
  (−)cyanopindolol, 1397
  cyclazocine, 479, 597
  cyclizine, 925
  cyclohexylideneethyl-5-barbitoric acid, 727
  cyproheptadine, 1057
  [D-Arg^2, Sar^4]-demorphin (1–4), 27
  desipramine, 135, 155, 1715
  desmethylimipramine, 1039, 1101, 1361
  dexoxadrol, 417
  dextrofenfluramine, 647
  dextrorphan, 417
  diazepam, 319, 323, 513, 597, 701, 823, 963, 1007, 1071, 1471, 1479, 1491
  dichlorous, 737
  diethyldithiocarbamic acid, 631
  N,N-diethyltryptamine (DET), 381
  4,5 dihydroxyisophtalic acid, 497
  5,6-dihydroxytryptamine (5,6-DHT), 1509
  5,7-dihydroxytryptamine (5,7-DHT), 347, 955, 1039, 1679
  5-hydroxytryptophan (5-HTP), 1679
  diisopropylphosphorofluoridate (DFP), 733, 737, 941, 1077
  1-(2,5-dimethoxyphenyl)-2-amino-propane hydrochloride (2,5-DMA), 43
  N,N-dimethyltryptamine (DMT), 381, 393, 401
  diphenhydramine, 925
  disulfoton, 733
  DOB, 393
  L-dopa, 433, 1195
  dopamine, 223, 253, 751, 1161, 1189, 1533
  ethanol, 33, 55, 93, 165, 463, 485, 491, 519, 543, 617, 625, 769, 801, 813, 869, 895, 955, 967, 1083, 1089, 1115, 1137, 1167, 1263, 1305, 1343, 1369, 1417, 1659, 1813, 1825
  ethanolamine O-sulphate, 1065
  ethosuximide, 555, 1583
  ethyl-β-carboline-3-carboxylate, 963
  d-ethylketazocine, 1761
  l-ethylketazocine, 1761
  etonitazene, 1095
  etorphine, 1761

eucatropine, 581
fenfluramine, 43, 1203, 1533, 1547
fentanyl, 785
FG 7142, 525, 1645
[^{3}H]flunitrazepam, 1, 1215
fluoxetine, 199, 281, 347, 351
fluphenazine, 1189
flurazepam, 841, 855, 875
fluoxetine, 1361
gepirone, 701
haloperidol, 205, 351, 693, 751, 781, 837, 983, 1161, 1409, 1423, 1445, 1509, 1561, 1593, 1785, 1821
halothane, 949
hemicholinium, 1509
heparin, 1543
heroin, 61, 1761
hexamethonium, 1509, 1821
hexocyclium, 581
histidine, 1323
L-histidine, 571
histrionicotoxin, 417
homatropine, 581
Hydergine®, 1123
6-hydroxydopamine (6-OHDA), 15, 773, 1039, 1101, 1185, 1397, 1441, 1509, 1821
5-hydroxyindoleacetic acid (5HIAA), 1175
8-hydroxy-2-(N-di-n-propylamino)tetralin hydrobromide (8OHDPAT), 43, 1479, 1513
2-(β-(4-hydroxyphenyl)-ethyl-aminomethyl)-tetralone (BE 2254), 1397
(+)3-(3-hydroxyphenyl)-N-*n*-propyl-piperidine((+)3-PPP), 1409
(−)3)(3-hydroxyphenyl)-N-*n*-propyl-piperidine ((−)3-PPP), 1409
5-hydroxytryptamine (5HT), 39, 1133, 1467, 1479
5-hydroxytryptophan (5HTP), 341, 537, 1175
L-5-hydroxytryptophan, 351, 1275
ICI-154,129, 561, 1235
imipramine, 1275
indalpine, 1471
inosine, 121, 963
iodine-131, 1593
isapirone, 1513
isofloxythepin, 1445
isoproterenol, 721
kainic acid, 107, 1101, 1353
ketamine, 347, 417
ketocyclazocine, 561
kynurenine, 1215
lead, 211, 819
leptazol, 823
lergotrile mesylate, 67
levorphanol, 417
levoxadrol, 417
lidocaine, 1429
lisuride, 365
lithium, 9, 883
lorazepam, 855
lysergic acid diethylamide (LSD), 43, 183, 335, 351, 359, 365, 381, 393, 401, 407, 677, 1203, 1293
lysergic acid diethylamide-25 (LSD-25), 341
magnesium, 949
marijuana, 1749
mazindol, 1665
mecamylamine, 1509, 1767, 1821
meperidine, 597, 1247
3-mercaptopropionic, 1065
mescaline, 381, 393
metaphit, 1403
metergoline, 351, 919
methadone, 597
methamphetamine, 571, 693
methionine, 1323
methiothepin, 537
methoxamine, 39
5-methoxy N,N-dimethyltryptamine (5-MeODMT), 347, 381, 1513
5-methoxy-N,N-dimethyltryptamine hydrogen oxalate (5-OMe DMT), 43
3-methoxy-4-hydroxyphenylethyl-eneglycol sulfate (MHPG-SO_4), 115
methylazoxymethanol, 975
methyl-β-carboline-3-carboxylate (β-CCM), 1487
4-methyl 2,5-dimethyloxyamphetamine (DOM), 381, 393
2-methyl-3,3-diphenyl-3-propanolamine (2-MDP), 23
3,4-methylenedioxyamphetamine (TMA), 381
3,4-methylenedioxymetham-phetamine (MDMA), 1533
methylnalorphinium, 829
methylphenidate, 211, 425, 503
methylscopolamine, 1635
methysergide, 341, 537, 1057, 1133, 1509, 1821
methylxanthine, 1333
mianserin, 135, 341, 351, 1275
MJ 13805, 1479
MK-801, 241
monosodium glutamate, 549, 1343
morphine, 27, 71, 151, 155, 319, 479, 597, 849, 911, 931, 1083, 1241, 1629, 1687, 1739, 1761
morphine sulfate, 561, 757
MR 2266, 861
muscimol, 673, 1065, 1189
naloxone, 27, 151, 155, 183, 309, 315, 439, 507, 597, 733, 829, 833, 849, 861, 899, 1129, 1241, 1461, 1779
naloxone hydrochloride, 561
naloxazone, 1235, 1461
naloxonazine, 1721
naltrexone, 155, 899
neostigmine, 519
nicotine, 99, 159, 171, 567, 743, 769, 883, 1509, 1605, 1767
nitrazepam, 1471, 1479
norcocaine, 305
norepinephrine, 1015
parachlorophenylalanine (PCPA), 347, 1479
parathion, 737
paraxanthine, 1281
pargyline, 1101, 1275
penicillin, 1241
pentazocine, 925
d-pentazocine, 1761
l-pentazocine, 1761
pentobarbital, 55, 93, 597, 801, 855, 875, 999, 1071, 1215, 1305, 1805
pentylenetetrazol, 841, 1383
perphenazine, 1445
phencyclidine (PCP), 23, 127, 187, 347, 417, 597, 1275, 1403, 1629
phenobarbital, 555, 895, 1383, 1651
phenobarbitone, 193
phenoxybenzamine, 1509, 1821
phentolamine, 613, 1015
β-phenylethanolamine, 1547
β-phenylethylamine, 1141, 1547
phenylpropanolamine, 1665
phenylquinoline, 525
phenytoin, 193, 555, 1301, 1583
physostigmine, 381, 519
picrotoxin, 673, 1065
pilocarpine, 1157
pimozide, 259, 1445, 1527, 1577
pirenperone, 1161, 1479
piribedil, 531
pizotifen (BC-105), 677
PK 11195, 193, 1673
practolol, 1509, 1821
prazosin, 613, 1397
premazepam, 1479
progabide, 1301
promethazine, 925
propantheline, 581
propranolol, 155, 183, 1015, 1397, 1509, 1821
n-propylnorapomorphine, 469
psilocin, 335, 381, 393
psilocybin, 381
pumiliotoxin-β, 417
quinine, 1555
quinolinic acid, 1215
quinpirole hydrochloride, 721
quipazine, 43, 537, 1467
R1881, 285
reserpine, 347, 1275, 1445, 1457, 1509
ritanserin, 1479
Ro15-1788, 1645, 1703
RO5-3663, 823
Ro5-4864, 193, 525, 1673
Ro 15-1788, 121, 525, 855, 963, 999, 1263, 1487
RU 24213, 837
RU 24969, 1479
saccharin, 567, 833
salbutamol, 177
sarin, 941
satietin, 247
SCH 23390, 837, 919
scopolamine, 581, 715, 733, 819, 865, 1123, 1157, 1353, 1409, 1509, 1635, 1821
secobarbital, 727
semicarbazide, 497
serine, 1219
serotonin, 1057, 1203, 1533
SKF 38393, 837
SKF-10,047, 187
sodium pentobarbital, 963, 1147
sodium valproate, 823
soman, 845, 941
spiperone, 1445
^{3}H-spiroperidol, 253
sulpiride, 919, 1429, 1445, 1639
syrosingopine, 1457
tetrabenazine, 631
tetrahydro-β-carboline (THBC), 1203, 1533, 1733
4, 5, 6, 7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol; gaboxadol (THIP), 1007

theobromine, 1281
theophylline, 1281, 1333, 1599
thiopental, 895
thioridazine, 1639
tolazolamine, 1509
tracazolate, 525
tranylcypromine, 351
trazodone, 135
triazolam, 875
trifluoperazine, 1445
1-(3-trifluoromethylphenyl)piperazine (TFMPP), 43
trihexphenidyl, 581
3,4,5-trimethoxyamphetamine (TMA), 381
tryptamine, 393
tryptophan, 347, 1275
L-tryptophan (LTP), 1491
TVXQ 7821, 1479
U-50, 488H, 561
valproic acid, 555, 1007, 1383, 1583
vanadate, 1503
verapamil, 187, 329
vincamine, 1123
vinpocetine, 1123
xylamidine, 677
yohimbine, 613, 829, 1015, 1203, 1509, 1821
zimeldine, 199, 463, 1471
ZK 93426, 525
zotepine, 1445
Drug comparisons
chlordiazepoxide, 895
cholecystokinin octapeptide (CCK-8), 983
circling behavior, 983
clozapine, 983
ethanol, 895
hallucinogens, 365, 381
haloperidol, 983
limb jerk, 381
lisuride, 365
lysergic acid diethylamide (LSD), 365
monkeys, 381
narcotic reactions, 895
phenobarbital, 895
primate model, 381
primate social behavior, 381
selective breeding, 895
sleep time, 895
thiopental, 895
tolerance, 381
Drug differences
amphetamine, 1739
antihistaminic drugs, 925
antinociception, 925
caudate nucleus, 1739
drug interactions, 925
locomotor activity, 1739
morphine, 1739
septal nucleus, 1739
Drug discrimination
amphetamine, 205
d-amphetamine, 765, 1301, 1665
benzodiazepine antagonists, 999
cathinone, 205, 1161
central nervous system (CNS), 1203
chlordiazepoxide, 999
cocaine, 205, 765
cyclazocine, 479
dose-response relationship, 769
drug history, 479
drug interactions, 999, 1301
duality of effect, 1533
ethanol, 769, 1301
fenfluramine, 1547
human studies, 1665
isomers, 1161
mazindol, 1665
3,4-methylenedioxymethamphetamine (MDMA), 1533
monkeys, 765
morphine, 479
nicotine, 769
pentobarbital, 999, 1301
β-phenylethanolamine, 1547
β-phenylethylamine, 1547
phenylpropanolamine, 1665
pigeons, 479, 1301
route of administration, 765
serotonergic mediation, 1203
stimulus properties, 1161
subjective effects, 1665
tetrahydro-β-carboline (THBC), 1203
Drug history, 479
cyclazocine
drug discrimination
morphine
pigeons
Drug interactions
active avoidance, 631
aggression, 1821
d-amphetamine, 1305
angiotensin II, 721
animal models, 781
antihistaminic drugs, 925
antinociception, 925
ascorbic acid, 781
atropine, 845
baclofen, 1301
behavioral effects, 341
behavioral tolerance, 845
benzodiazepine antagonists, 963, 999
catalepsy, 781
catecholamine mechanisms, 571
catecholamines, 631
cats, 351, 1821
chlordiazepoxide, 999
color tracking procedure, 597
conditioned avoidance response, 433
diazepam, 963, 1071
drinking, 721
dogs, 1071
drug differences, 925
drug discrimination, 1305
eating, 561, 899
endogenous opioids, 899
ethanol, 1263, 1305
fixed interval/fixed ratio schedule, 1071
gerbils, 315
hallucinogens, 351
haloperidol, 781
hamsters, 849
head shaking, 433
L-histidine, 571
6-hydroxydopamine (6-OHDA), 1821
hyperactivity, 849
hypertonic saline, 721
insulin, 899
in vivo, 1301
isoproterenol, 721
jump test, 1721
locomotor activity, 571
lordosis, 1015
luteinizing hormone-releasing hormone (LHRH), 433
lysergic acid diethylamide-25 (LSD-25), 341
mecamylamine, 1767
medial preoptic area, 1015
medial septum, 1263
memory retention, 631
methamphetamine, 571
monkey/pigeon comparisons, 963
morphine, 849
morphine analgesia, 1721
morphine discrimination, 597
naloxonazine, 1721
naloxone, 849
neurochemical effects, 341
neurotoxicity, 1301
nicotine, 1767
nicotinic effects, 1767
norepinephrine, 1015
opioid receptors, 1629
opioids, 561
organophosphates, 845
passive avoidance, 631
pentobarbital, 999, 1071, 1305
phencyclidine (PCP), 1629
phenytoin, 1301
pigeons, 597, 1305
progabide, 1301
protein synthesis inhibitors, 631
quinpirole, 721
raphe unit activity, 351
righting reflex, 1263
righting response, 963
seizures, 1301
serotonin receptors, 351
slugs, 561
soman, 845
spontaneous motor activity, 433
stereotypy, 1629
strain differences, 1767
stroke, 315
survival effect, 315
tail flick, 1721
thyrotropin-releasing hormone (TRH), 1263
Drug-opiate interaction, 1779
apomorphine
grooming
naloxone
opiates
stretching
yawning
Drug sensitivity, 1793
amphetamine
cocaine
housing conditions
place preference
Drug tolerance, 865
anticholinergic sensitivity
exercise, chronic
muscarinic antagonists
Duality of effect, 1533
dose-response relationship
drug discrimination
3,4-methylenedioxymethamphetamine (MDMA)
Dyskinesia, 1203
amphetamine
calcitonin
locomotor activity
Dysmorphogenesis, 165
behavioral pathogenesis

Fetal Alcohol Syndrome, 165, 625
pregnancy

Eating
BAT thermogenesis, 605
body weight, 605
brown adipose tissue (BAT), 1605
chickens, 39
clonidine, 1567
corticosterone, 911
diurnal rhythm, 911
dopamine agonists, 1195
dose response, 247
drinking, 491, 605
drug interactions, 561, 899
endogenous opioids, 899
ethanol, 491
experience, 259
food competition, 1567
5-hydroxytryptamine (5-HT), 39
hypokinesia, 259
insulin, 899
lesions, 6-hydroxydopamine (6-OHDA), 931
lesions, PVN electrolytic, 931
macronutrient selection, 931
methoxamine, 39
monkeys, 491, 1567
morphine, 911, 931
motivation, 259
neurotensin, 1195
nicotine, 1605
opioids, 561, 833
oral sensory function, 833
phenylpropanolamine, 605
pimozide, 259
route of administration, 247
satietin, 247
slugs, 561
stress, 491
taste preference, 833
thermogenesis, 1605
Eating rate, 1133
feeding bouts
microstructural analysis
peripheral 5-HT
satiety
EEG discharges, 1241
convulsions
morphine
naloxone
penicillin
rabbits
Electrocortical activity, 99
catecholamines
nicotine
Electrophysiological responsiveness, 1397
β-adrenergic receptors
hippocampus
lesions, DSP4
norepinephrine concentration
Emotional reactivity, 879
alcohol preference
strain differences
Enantiomers, 281
p-chloroamphetamine
fluoxetine
serotinin uptake
Endogenous β-carboline, 1219
hormones
platelet rich plasma
porphyria
Endogenous opioids, 899
drug interactions
eating
insulin
β-Endorphin
choice paradigm, 507
ethanol, 1343
hypothalamic arcuate nucleus, 1343
lordosis, 1235
neonatal monosodium glutamate, 1343
neurosensitivity, 1343
open field, 1235
opioid receptors, 1235
opioids, 507
sociosexual proclivity, 507
Escape, 497
GAD inhibitors
medial hypothalamic
mesencephalic central gray
Estradial, 139
climbing
Ethanol
activity stress, 869
adrenal medulla, 33
d-amphetamine, 1305
barbital, 801
Ca^{++} uptake, 1659
calcium, 949
calmodulin, 1659
cardiac hypertrophy, 33
catecholamines, 33
central cholinergic system, 519
chlordiazepoxide, 93, 895
conditioned taste aversion, 463
cross-tolerance, 801
dose-response relationship, 769, 1305
drinking, 491, 869
drinking suppression, 463
drug comparisons, 895
drug discrimination, 769, 1305
drug interactions, 1263, 1305
eating, 491
β-endorphin, 1343
hamsters, 967
hereditary cardiomyopathy, 967
hypothalamic arcuate nucleus, 1343
inbred strains, 1417
intersubject variability, 485
low-dose ethanol effects, 617
medial septum, 1263
memory, 1813
memory dysfunction, 519
monkeys, 485, 491
mortality, 869
narcotic reactions, 895
neonatal monosodium glutamate, 1343
neuronal sensitivity, 949
neuronal uptake, 55
neurosensitivity, 1343
nicotine, 769
oral self-administration, 1417
pentobarbital, 55, 93, 801, 1305
pharmacokinetics, 485
phenobarbital, 895
pigeons, 1305
post-learning effects, 1813
righting reflex, 1263
righting response, 967
selective breeding, 895, 949
sex differences, 967
sleep time, 895
sodium excretion, 967
spontaneous alternation, 519
spontaneous motor activity, 617
stimulus control, 1813
strain differences, 617, 967
stress, 491
synaptosomal membranes, 1659
thiopental, 895
thyrotropin-releasing hormone (TRH), 1263
tolerance, 93, 801
ulcer development, 869
water excretion, 967
water-finding task, 1813
zimeldine, 463
Ethanol-induced CNS depression, 543
L-ascorbic acid
ethanol-induced hypnosis
motor coordination
Ethanol-induced hypnosis, 543
L-ascorbic acid
ethanol-induced CNS depression
motor coordination
Ethanol intoxication, 1115
adenylate cyclase
genetic breeding
motor impairment
Na+K-ATPase
5′-nucleotidase
Ethanol preference, 1089
drinking
genetic differences
Ethanol selection, 1825
dietary salt-loading
drinking
thirst
Ethanol self-administration, 1369
conditioned place aversion
reinforcement
Ethanol sensitivity, 1137
depolarization-dependent calcium levels
strain differences
Ethanol stimulatory effect, 1225
genetics
locomotor activity
tolerance
Ethanol tolerance, 955
5,7-dihydroxytryptamine (5,7-DHT)
serotonergic system
Ethanol treatment, 813
hypovolemia
plasma angiotension II and III
receptor binding
Etonitazene, 1095
food deprivation
pharmacogenetics
strain differences
Exercise, chronic, 865
anticholinergic sensitivity
drug tolerance
muscarinic antagonists
Excitatory amino acids, 23
2-methyl-3,3-diphenyl-3-propanol-amine (2-MDP)
phencyclidine (PCP)
Experience, 259
eating
hypokinesia
motivation
pimozide
Exploration, 469

caerulein
dopamine$_2$-receptors
serotonin$_2$-receptors
Exploratory activity, 525
anxiety
anxiogenic drug effects
anxiolytic drug effects
Extrapyramidal motor effects, 1409
antipsychotic drugs
dopaminergic neurotransmission
locomotor activity
Eye tracking, 693
dopaminergic agents
methamphetamine
monkeys

Feeding behavior, 1315
cerebral amino acids
hyperosmotic environment
toads
Feeding bouts, 1133
eating rate
microstructural analysis
peripheral 5-HT
satiety
Feeding-related changes, 575
catecholamine release
locomotor activity
Feeding response, 1189
dopamine
muscimol
nucleus accumbens
nucleus raphe dorsalis
Fenfluramine, 1547
drug discrimination
β-phenylethanolamine
β-phenylethylamine
Fentanyl, 785
brain water content
central venous pressure
intracranial pressure
lesions, parieto-occipital cortex
rabbits
systolic-arterial pressure
Fetal Alcohol Syndrome
animal model, 625
behavioral pathogenesis, 165
drinking fluid with ethanol, 625
dysmorphogenesis, 165
pregnancy, 165, 625
Fixed interval/fixed ratio schedule, 1071
diazepam
dogs
drug interactions
pentobarbital
Fixed ratio schedule, 401
N,N-dimethyltryptamine (DMT)
lysergic acid diethylamide (LSD)
opioid-hallucinogen interactions
Flinch jump threshold, 687
active avoidance
cerebral embolization
memory impairment
passive avoidance
[^{3}H]Flunitrazepam binding, 1215
inhibitory effect
kynurenine
pentobarbital stimulation
quinolinic acid
Fluoxetine
avoidance, 199
p-chloroamphetamine, 281
enantiomers, 281
olfactory bulbectomy, 199
serotonin uptake, 281
Y-maze, 199
zimeldine, 199
Flurazepam, 841
benzodiazepine-receptor ligands
β-carboline
convulsions
Food competition, 1567
clonidine
eating
monkeys
Food deprivation
alcohol consumption, 271
caffeine, 1555
conflict, 271
etonitazene, 1095
pharmacogenetics, 1095
sex differences, 1555
strain differences, 1095
stress, 271
two-bottle preference, 1555
unavoidable shock, 271
Food intake, 1817
body weight
pituitary-thyroid axis
thyrotropin-releasing hormone (TRH)
Foot shock
adrenergic receptor changes, 1587
analgesia, 791
antinociception, 791
humoral mediation, 791
stress, 1587
Footshock-induced analgesia, 1257
cimetidine
H_2-receptor
Formalin test
analgesia, 319
antinociception, 709
p-chloroamphetamine, 709
diazepam, 319
hot plate, 709
lesions, ascending serotonergic pathways, 709
morphine, 319
stress, 319
tail flick, 709
Freund's adjuvant, 49
chronic pain
inflammation
nociception
Functional tolerance, 1805
chronic administration
motor coordination
phenobarbital

GABA agonists, 1
benzodiazepine binding sites
kidneys, mice
GABA receptors, 665
seizures
strain differences
GABAergic neurotransmission, 673
lordosis
ventromedial hypothalamus
GABAergic transmission, 1065
sexual behavior, male rats
GABAmimetic drugs
air blast stimulation, 1007
anticonvulsant effects, 1007
gerbils, epilepsy prone, 1007
mouse killing behavior, 657
olfactory bulb, 657
tolerance, 1007
GAD inhibitors, 497
escape
medial hypothalamus
mesencephalic gray
Genetic analysis, 743
diallel cross
nicotine
open field
Genetic breeding, 1115
adenylate cyclase
ethanol intoxication
motor impairment
Na+K-ATPase
5′-nucleotidase
Genetic crossing, 1333
inbred strains
locomotor activity
methylxanthines
Genetic differences, 1089
drinking
ethanol preference
Genetics, 1225
ethanol stimulating effect
locomotor activity
tolerance
Gepirone, 701
anxiety
buspirone
conflict
lesions, 5,7-dihydroxytryptamine (5,7-DHT)
serotonergic mechanisms
Gerbils
catechol-O-methyltransferase, 1141
drug interactions, 315
β-phenylethylamine, 1141
red blood cell enzymes, 1141
stroke, 315
survival effect, 315
Gerbils, epilepsy prone, 1007
air blast stimulation
anticonvulsant effects
GABAmimetic drugs
tolerance
Glucocorticoids, 1651
adrenalectomy
hypnotic response
hypothermia
phenobarbital
Glutamate, 549
aggression
asymmetry
chickens
copulation
Grooming
d-amphetamine, 1025
apomorphine, 1779
dopamine agonists, 837
dopamine antagonists, 837
dopamine neurotransmission, 1185
drug-opiate interaction, 1779
lesions, nucleus accumbens, 1185
naloxone, 1779
opiates, 1779
oxytocin, 1185
proximity, 1025
social behavior, 1025

stretching, 1779
stumptail macaques, 1025
yawning, 1779

H_2-Receptor, 1257
cimetidine
footshock-induced analgesia
Hallucinogen research, 407
lysergic acid diethylamide (LSD)
psychedelic effects
Hallucinogens
cats, 347, 351
chronic spinal dogs, 393
dorsal root potentials, 347
drug comparisons, 365, 381
drug interactions, 351
limb jerk, 381
lisuride, 365
lysergic acid diethylamide (LSD), 359, 365
molecular structure, 335
monkeys, 381
primate model, 381
primate social behavior, 381
raphe unit activity, 351
serotonergic neuronal systems, 359
serotonin receptors, 351
structure-activity relationship, 335
tolerance, 393
tryptaminergic pathways, 393
tryptamines, 335
Haloperidol
amygdaloid complex, 1561
animal models, 781
apomorphine, 1593
ascorbic acid, 781
catalepsy, 781, 1785
cholecystokinin octapeptide (CCK-8), 983
chronic administration, 1561
circling behavior, 983
clozapine, 983, 1561
dopamine receptors, 1593
drug comparisons, 983
drug interactions, 781
hypothyroidism, 1593
locomotor activity, 1593
MSH-release inhibiting factor-1 (MIF-1), 1785
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 1785
Hamilton search task, 819
lead exposure
memory
monkeys
scopolamine
Hamsters
conditioned taste aversion, 567
drug interactions, 849
ethanol, 967
hereditary cardiomyopathy, 967
hyperactivity, 849
morphine, 849
naloxone, 849
nicotine, 567
righting response, 967
saccharin, 567
sex differences, 967
sodium excretion, 967
strain differences, 967
water excretion, 967
Handling, 1151
hypothalamic norepinephrine
plasma corticosterone
social isolation
stressors, acute and chronic
Hangover effects, 875
hypnotics
monkeys
sleep-inducing doses
Harmanes, 1219
endogenous β-carboline
platelet rich plasma
porphyria
Head shaking, 433
conditioned avoidance response
drug interactions
luteinizing hormone-releasing hormone (LHRH)
spontaneous motor activity
Heart rate
angiotensin II, 1573
arterial pressure, 1573
atrial natriuretic factor (ANF), 1573
classical conditioning, 677
drinking, 1573
lysergic acid diethylamide (LSD), 677
orienting reflex, 677
pizotifen (BC-105), 677
rabbits, 677
xylamidine, 677
Hereditary cardiomyopathy, 967
ethanol
hamsters
righting response
sex differences
sodium excretion
strain differences
water excretion
Hippocampal circuitry, 1403
metaphit
neuronal heterogeneity
phencyclidine (PCP)
Hippocampal kindling, 777
N-[2-chloroethyl]-N-ethyl-2-bromobenzyl-amine (DSP4)
limbic seizures
noradrenaline depletion
wet dog shakes
Hippocampus
β-adrenergic receptors, 1397
anxiety, 1733
electrophysiological responsiveness, 1397
indole-aldehyde adduct, 1733
lesions, DSP4, 1397
lysergic acid diethylamide (LSD), 183
norepinephrine concentration, 1397
open field behavior, 1733
rabbits, 183
tetrahydro-β-carboline (THBC), 1733
theta rhythms, 183
L-Histidine, 571
catecholamine mechanisms
drug interactions
locomotor activity
methamphetamine
Histidyl-proline, 1229
locomotor activity
open field behavior
visual discrimination
Hormone
corticosterone, 911
cortisol, 1749
estradiol, 139
estradiol benzoate, 285, 1015
estrogen, 673
insulin, 899
norepinephrine (NE), 1397
progesterone, 673, 1015
prolactin, 1749
testosterone, 1749
testosterone propionate, 285
Hormone levels, 1749
behavioral effects
human studies, males
marijuana
subjective effects
Hot plate
antinociception, 425, 709
p-chloroamphetamine, 709
dopamine agonists, 425
dopamine antogonists, 425
formalin test, 709
lesions, ascending serotonergic pathways, 709
neurotensin, 425
tail flick, 709
Housing conditions, 1793
amphetamine
cocaine
drug sensitivity
place preference
5-HT syndrome, 1513
differential effects
5-HT turnover, 79
5-HT_{1A} selective drugs
dopamine turnover
hypothermia
stress
5-HT_{1A} selective drugs, 1513
differential effect
5-HT syndrome
Human serum albumin, 1031
anti-inflammatory drug binding
indomethacin
indoprofen
Human studies
d-amphetamine, 1665
atropine, 1111
cigarette smoke yields, 587
cigarettes, 171
deprivation, 171
drug discrimination, 1665
inhalation volumes, 587
mazindol, 1665
nicotine, 171
performance assessment battery, 1111
phenylpropanolamine, 1665
psychometrics, 1111
reinforcement, 171
smoke absorption, 587
stress, mental, 1521
subjective effects, 1665
urinary monoamine metabolites, 1521
Human studies, females, 309
hypothalamic-anterior-pituitary axis
menstruation
naltrexone
Human studies, males
acute and chronic administration, 1491
behavioral effects, 1749
diazepam, 1491
hormone levels, 1749
5-hydroxytryptamine (5-HT) function,

1491
[3]H-imipramine binding, 1491
marijuana, 1749
subjective effects, 1749
L-tryptophan, 1491
Humoral mediation, 791
analgesia
antinociception
foot shock
Hydergine®, 1123
aniracetam
hypoxia
passive avoidance
scopolamine
vincamine
vinpocetine
6-Hydroxydopamine (6-OHDA)
aggression, 773, 821
apomorphine, 773
caffeine, 1039
catecholaminergic pathways, 1441
cats, 1821
5,7-dihydroxytryptamine (5,7-DAT), 1039
drug interactions, 1821
hypertension, 15
locomotor activity, 15, 1039
locus coeruleus, 773
monoamine levels, 1039
nociception, 1441
open field, 15
spinal cord, 1441
5-Hydroxytryptamine (5-HT)
animal models, 1479
anxiety, 1467, 1479
chickens, 39
eating, 39
methoxamine, 39
serotonergic function, 1467
5-Hydroxytryptamine (5-HT) function, 1491
acute and chronic administration
diazepam
human studies, males
[3]H-imipramine binding
L-tryptophan
Hyperactivity
drug interactions, 849
hamsters, 849
latent inhibition, 975
methylazoxymethanol, 975
microencephaly, 975
morphine, 849
naloxone, 849
taste aversion, 975
Hyperosmotic environment, 1315
cerebral amino acids
feeding behavior
toads
Hypertension
6-hydroxydopamine (6-OHDA), 15
locomotor activity, 15
open field, 15
sodium intake, 1167
strain differences, 1167
voluntary ethanol consumption, 1167
Hypertonic saline, 721
angiotensin II
drinking
drug interactions
isoproterenol
quinpirole
Hypnotic response, 1651
adrenalectomy
glucocorticoids
hypothermia
phenobarbital
Hypnotics, 875
hangover effects
monkeys
sleep-inducing doses
Hypokinesia, 259
eating
experience
motivation
pimozide
Hypomotility, 1639
apomorphine
dopamine receptors
neuroleptics, atypical
stereotyped behaviors
Hypothalamic-anterior-pituitary axis, 309
human studies, females
menstruation
naltrexone
Hypothalamic arcuate nucleus, 1343
β-endorphin
ethanol
neonatal monosodium glutamate
neurosensitivity
Hypothalamic norepinephrine, 1151
handling
plasma corticosterone
social isolation
stressors, acute and chronic
Hypothalamus, 1175
neonatal manipulation
serotonin levels
sexual activity
Hypothyroidism, 1593
apomorphine
dopamine receptors
haloperidol
locomotor activity
Hypothermia
adrenalectomy, 1651
diisopropylfluorophosphate (DFP), 1077
dopamine, 79
glucocorticoids, 1651
5-HT turnover, 79
hypnotic response, 1651
locomotor activity, 1077
phenobarbital, 1651
strain differences, 1077
stress, 79
Hypovolemia, 813
ethanol treatment
plasma angiotensin II and III
receptor binding
Hypoxia
anitracetam, 1123
Hydergine®, 1123
locomotor activity, 1687
morphine, 1687
neurotransmitter metabolism, 1687
passive avoidance, 1123
scopolamine, 1123
vincamine, 1123
vinpocetine, 1123

Ibotenic acid, 1287
behavioral recovery time
lesions, nucleus basalis
ICV injections, 263
adenosine analogues
locomotor activity
Illumination, 503
age differences
amphetamine
methylphenidate
response speed
squirrel monkeys
[3]H-Imipramine binding, 1491
acute and chronic administration
diazepam
human studies, males
5-hydroxytryptamine (5-HT) function
L-tryptophan
Implantation, 1809
cannula
construction
multiple microinjections
Inbred strains
ethanol, 55, 1417
genetic crossing, 1333
locomotor activity, 1281, 1333
methylxanthines, 1281, 1333
neuronal uptake, 55
oral self-administration, 1417
pentobarbital, 55
Incentive contrasts, 1577
brain stimulation reward
pimozide
Indole-aldehyde adduct, 1733
anxiety
hippocampus
open field behavior
tetrahydro-β-carboline (THBC)
Indomethacin, 1031
anti-inflammatory drug binding
human serum albumin
indoprofen
Indoprofen, 1031
anti-inflammatory drug binding
human serum albumin
indomethacin
Inescapable shock, 1673
peripheral type benzodiazepine receptors
Ro 5-4864 binding
stress
Inflammation, 49
chronic pain
Freund's adjuvant
nociception
Infrared beam device, 1789
personal computer
Ingestion, 217
chlordiazepoxide
palatability
Inhalation volumes, 587
cigarette smoke yields
human studies
smoke absorption
Inhibition, 1599
aminophylline
amygdala
kindling
seizures
Inhibition and facilitation, 1461
lordosis
morphiceptin
naloxazone
naloxone
Inhibitory effect, 1215

[^{3}H]flunitrazepam binding
kynurenine
pentobarbital stimulation
quinolinic acid
Inosine, 121
benzodiazepine receptors
pigeons
punished behavior
Insulin, 899
drug interactions
eating
endogenous opioids
Intersubject variability, 485
ethanol
monkeys
pharmacokinetics
Intracerebral dialysis, 1755
dopamine release, drug-induced
locomotor activity
stereotyped behavior
Intracranial pressure, 785
brain water content
central venous pressure
fentanyl
lesions, parieto-occipital cortex
rabbits
systolic arterial pressure
Intracranial self-administration, 1429
cocaine
medial prefrontal cortex
neuronal systems
Intracranial self-stimulation, 193
benzodiazepine antagonists
Ro 5-4864
Intrinsic neurons, 1101
catecholamine terminals
neonatal dopamine depletion
self-stimulation
ventral tegmentum
In vivo, 1301
baclofen
drug interactions
neurotoxicity
phenytoin
progabide
seizures
Isofloxythepin, 1445
convulsions, post-decapitation
prolactin secretion
zotepine
Isomers, 1161
cathinone
drug discrimination
stimulus properties
Isoproterenol, 721
angiotensin II
drinking
drug interactions
hypertonic saline
quinpirole

Jump test, 1721
drug interactions
morphine analgesia
naloxonazine
tail flick
Jumping behavior, 1423
accute vs. chronic effects
locomotor activity
thyrotropin-releasing hormone (TRH)
Juvenile rats, 455
amphetamine
locomotor activity
play behavior

Kidneys, mice, 1
benzodiazepine binding sites
GABA agonists
Kindling
aminophylline, 85, 1599
amygdala, 1599
dentate gyrus, 85
inhibition, 1599
perforant path stimulation, 85
seizures, 1599
Kynurenine, 1215
[^{3}H]flunitrazepam binding
inhibitory effect
pentobarbital stimulation
quinolinic acid

Latent inhibition, 975
hyperactivity
methylazoxymethanol
microencephaly
taste aversion
Lead, 211
amphetamine
discrimination
Lead exposure, 819
Hamilton search task
memory
monkeys
scopolamine
Learned helplessness
β-adrenoreceptors, 177
calcium, 445
clenbuterol, 177
depression, 445
salbutamol, 177
serotonin metabolism, 445
shuttle-box, 177
Learning
amphetamine, 1617
lesions, septum, 1635
medial prefrontal cortex, 1617
methylscopolamine, 1635
scopolamine, 1635
seizures, 1617
self-stimulation, 1617
shock escape, 1635
Learning and retention, 905
atropine
caudate-putamen
negative reinforcer
passive avoidance
retrograde amnesia
Learning/memory tests, 1611
brain serotonin metabolism
open field
portacaval shunt
somatosensory reactivity
Lergotrile, 67
conditioned avoidance
prolactin
Lesions, ascending serotonergic pathways, 709
antinociception
p-chloroamphetamine
formalin test
hot plate
tail flick

Lesions, basal forebrain, 1353
alternation
memory
scopolamine
spatial discrimination
Lesions, 5,7-dihydroxytryptamine (5,7-DHT), 701
anxiety
buspirone
conflict
gepirone
serotonergic mechanisms
Lesions, DSP4, 1397
β-adrenergic receptors
electrophysiological responsiveness
hippocampus
norepinephrine concentration
Lesions, 6-hydroxydopamine (6-OHDA)
eating, 931
lesions, PVN electrolytic, 931
macronutrient selection, 931
morphine, 931
rigid dopamine analogues, 253
stereotypy, 253
striatal response, 253
Lesions, hypothalamus, 1047
amphetamine
anorexia, amphetamine induced
Lesions, kainic acid, 107
lesions, lateral septum
neurotoxic agents
psychoneuroendocrine functions
Lesions, lateral septum, 107
lesions, kainic acid
neurotoxic agents
psychoneuroendocrine functions
Lesions, N-methyl-D-aspartate, 1829
D_2 receptors
lesions, prefrontal cortex
locomotor activity
stereotypy
Lesions, nucleus accumbens, 1185
dopamine neurotransmission
grooming
oxytocin
Lesions, nucleus basalis, 1287
behavioral recovery time
ibotenic acid
Lesions, parieto-occipital cortex, 785
brain water content
central venous pressure
fentanyl
intracranial pressure
rabbits
systolic arterial pressure
Lesions, prefrontal cortex, 1829
D_2 receptors
lesions, N-methyl-D-aspartate
locomotor activity
stereotypy
Lesions, PVN electrolytic, 931
eating
lesions, 6-hydroxydopamine (6-OHDA)
macronutrient selection
morphine
Lesions, septum, 1635
learning
methylscopolamine
scopolamine
shock escape
Lesions, visual cortex, 71

conditioned taste aversion
morphine
place conditioning
Limb jerk, 381
drug comparisons
hallucinogens
monkeys
primate model
primate social behavior
tolerance
Limbic seizures, 777
N-[2-chloroethyl]-N-ethyl-2-bromo-benzyl-amine (DSP4)
hippocampal kindling
noradrenaline depletion
wet dog shakes
Lisuride, 365
drug comparisons
hallucinogens
lysergic acid diethylamide (LSD)
Lithium
adenosine, 9
amphetamine, 883
classical conditioning, 883
conditioned drug effects, 883
conditioned taste avoidance, 883
cortical cyclic AMP, 9
nicotine, 883
Locomotor activity
acute vs. chronic effects, 1423
adenosine analogues, 263
α-adrenoceptors, 305
amphetamine, 455, 1203, 1739
antidepressants, 1361
antipsychotic drugs, 1409
apomorphine, 291, 1593
autoreceptors, 291
barbiturates, 727
bin analysis, 1679
bupropion, 795
caffeine, 1039, 1695
calcitonin, 1203
catecholamine mechanisms, 571
catecholamine release, 575
caudate nucleus, 1739
ChE inhibition, 941
convulsant barbiturates, 727
cysteamine, 1703
D_2 receptor, 1829
development, 1377
developmental reflexes, 1695
dextrofenfluramine, 647
DHT model, 1679
dihydroxyphenylacetic acid (DOPAC), 795
5,7-dihydroxytryptamine (5,7-DHT), 1039
diisopropylfluorophosphate (DFP), 1077
diisopropylphosphorofluoridate (DFP), 941
dopamine, 223, 795
dopamine-mediated behavior, 1703
dopamine receptors, 305, 1593
dopamine release, drug induced, 1755
dopaminergic function, 449
dopaminergic neurotransmission, 1409
drug differences, 1739
drug interactions, 571
dyskinesia, 1203
ethanol stimulating effect, 1225
extrapyramidal motor effects, 1409
feeding-related changes, 575
genetic crossing, 1333
genetics, 1225
haloperidol, 1593
L-histidine, 571
histidyl-proline, 1229
6-hydroxydopamine (6-OHDA), 1039
hypertension, 15
hypothermia, 1077
hypothyroidism, 1593
hypoxia, 1687
ICV injections, 263
inbred strains, 1281, 1333
intracerebral dialysis, 1755
jumping behavior, 1423
juvenile rats, 455
lesions, N-methyl-D-aspartate, 1829
lesions, prefrontal cortex, 1829
mesolimbic system, 61
methamphetamine, 571
methylxanthines, 1281, 1333
monoamine levels, 1039
morphine, 1687, 1739
motor habituation, 1679
multiple amphetamine schedule, 449
multivariate statistics, 291
neonatal development, 537
neurotransmitter metabolism, 1687
norcocaine, 305
nucleus accumbens, 223
open field, 15
open field behavior, 1229
opiate receptors, 61
perinatal undernutrition, 449
play behavior, 455
postnatal exposure, lactation, 1695
prenatal stress, 1377
respiratory quotient, 647
sarin, 941
septal nucleus, 1739
serotonergic agonists, 537
serotonergic antagonists, 537
serotonergic neurons, 1377
soman, 941
somatostatin, 1703
stereotyped behavior, 1755
stereotypy, 449, 1703, 1829
strain differences, 1077
stress, chronic, 1361
striatal concentrations, 795
striatum, 223, 1703
taste preference, 1695
thyrotropin-releasing hormone (TRH), 1423
tolerance, 1225
total energy expenditure, 647
visual discrimination, 1229
Locomotor stimulant activity, 761
cocaine-caffeine interaction
dose-dependent effects
potentiation
Locus coeruleus, 773
aggression
apomorphine
6-hydroxydopamine (6-OHDA)
Long term consequences, 143
amino acid transport
blood-brain
protein metabolism
Lordosis
drug interactions, 1015
β-endorphin, 1235
GABAergic neurotransmission, 673
inhibition and facilitation, 1461
medial preoptic area, 1015
morphiceptin, 1461
naloxazone, 1461
naloxone, 1461
norepinephrine (NE), 1015
open field, 1235
opioid receptors, 1235
ventromedial hypothalamus, 673
Low-dose ethanol effects, 617
ethanol
spontaneous motor activity
strain differences
Luteinizing hormone-releasing hormone (LHRH), 433
conditioned avoidance response
drug interactions
head shaking
spontaneous motor activity
Lysergic acid diethylamide (LSD)
classical conditioning, 677, 1293
N,N-dimethyltryptamine (DMT), 401
drug comparisons, 365
fixed ratio schedule, 401
hallucinogen research, 407
hallucinogens, 359, 365
heart rate, 677
hippocampus, 183
lisuride, 365
nictitating membrane response, 1293
opioid-hallucinogen interactions, 401
orienting reflex, 677
pizotifen (BC-105), 677
psychedelic effects, 407
rabbits, 183, 677, 1293
serotonergic neuronal systems, 359
theta rhythms, 183
xylamidine, 677
Lysergic acid diethylamide-25 (LSD-25), 341
behavioral effects
drug interactions
neurochemical effects

Marijuana, 1749
behavioral effects
hormone levels
human studies, males
subjective effects
Mazindol, 1665
d-amphetamine
drug discrimination
human studies
phenylpropanolamine
subjective effects
Macronutrient selection, 931
eating
lesions, 6-hydroxydopamine (6-OHDA)
lesions, PVN electrolytic
morphine
Mecamylamine, 1767
drug interactions
nicotine
nicotinic effects
strain differences
Medial hypothalamus, 497
escape
GAD inhibitors
mesencephalic central gray

Medial prefrontal cortex
amphetamine, 1617
cocaine, 1429
intracranial self-administration, 1429
learning, 1617
neuronal systems, 1429
seizures, 1617
self-stimulation, 1617
Medial preoptic area, 1015
drug interactions
lordosis
norepinephrine
Medial septum
adrenocorticotropic hormone (ACTH), 1253
drug interactions, 1263
ethanol, 1263
open field behavior, 1253
righting reflex, 1263
self-stimulation, 1253
thyrotropin-releasing hormone (TRH), 1263
Melatonin, 1497
behavioral inhibition
benzodiazepines
differential reinforcement of low rates of response
Memory
alternation, 1353
cerebral embolization, 1729
choline acetyltransferase, 1729
ethanol, 1813
Hamilton search task, 819
lead exposure, 819
lesions, basal forebrain, 1353
monkeys, 819
passive avoidance, 1729
post-learning effects, 1813
scopolamine, 819, 1353
spatial discrimination, 1353
stimulus control, 1813
water-finding task, 1813
Memory dysfunction, 519
central cholinergic system
ethanol
spontaneous alternation
Memory impairment, 687
active avoidance
cerebral embolization
flinch jump threshold
passive avoidance
Memory retention, 631
active avoidance
drug interactions
passive avoidance
protein synthesis inhibitors
Menstruation, 309
human studies, females
hypothalamic-anterior-pituitary axis
naltrexone
Mesencephalic central gray, 497
escape
GAD inhibitors
medial hypothalamus
Mesolimbic system, 61
locomotor activity
opiate receptors
Metaphit, 1403
hippocampal circuitry
neuronal heterogeneity
phencyclidine (PCP)
Methamphetamine
catecholamine mechanisms, 571
dopaminergic agents, 693
drug interactions, 571
eye tracking, 693
L-histidine, 571
locomotor activity, 571
monkeys, 693
Method
chromatography, 1031
color tracking, 479, 597
formalin test, 319
Hamilton search task, 819
hanging stroke test, 315
high performance liquid chromatography (HPLC), 1219, 1491, 1695
high performance liquid chromatography with electrochemical detection (HPLC-EC), 1715
microstructural analysis, 1133
microwave irradiation, 151
push-pull perfusion, 575
radioimmunoassay, 1343, 1491
spectroscopy, 1031
swim task, 323
tail-flick test, 319
Methoxamine, 39
chickens
eating
5-hydroxytryptamine (5-HT)
Methylazoxymethanol, 975
hyperactivity
latent inhibition
microencephaly
taste aversion
Methyl-β-carboline-3-carboxylate (β-CCM), 1487
behavioral effects
dorsal raphe nucleus
microinjections
2-Methyl-3,3-diphenyl-3-propranolamine (2-MDP), 23
excitatory amino acids
phencyclidine (PCP)
3,4-Methylenedioxymethamphetamine (MDMA), 1533
dose-response relationship
drug discrimination
duality of effect
Methylnalorphinium, 829
analgesia, stress induced
cold-restraint stress
Methylphenidate, 503
age differences
amphetamine
illumination
response speed
squirrel monkeys
Methylscopolamine, 1635
learning
lesions, septum
scopolamine
shock escape
Methylxanthines
genetic crossing, 1333
inbred strains, 1281, 1333
locomotor activity, 1281, 1333
Microencephaly, 975
hyperactivity
latent inhibition
methylazoxymethanol
taste aversion
Microinjections, 1487
behavioral effects
dorsal raphe nucleus
methyl-β-carboline-3-carboxylate (β-CCM)
Microstructural analysis, 1133
eating rate
feeding bouts
peripheral 5-HT
satiety
Microwave irradiation, 151
morphine withdrawal
naloxone
wet dog shakes
Midazolam, 1057
anti-conflict action
benzodiazepines
consummatory contrast
Molecular structure, 335
hallucinogens
structure-activity relationship
tryptamines
Monkey/pigeon comparisons, 963
benzodiazepine antagonists
diazepam
drug interactions
righting response
Monkeys
d-amphetamine, 765
clonidine, 1567
cocaine, 765
dopaminergic agents, 693
drinking, 491
drug comparisons, 381
drug discrimination, 765
eating, 491, 1567
ethanol, 485, 491
eye tracking, 693
food competition, 1567
hallucinogens, 381
Hamilton search task, 819
hangover effects, 875
hypnotics, 875
intersubject variability, 485
lead exposure, 819
limb jerk, 381
memory, 819
methamphetamine, 693
pharmacokinetics, 485
primate model, 381
primate social behavior, 381
route of administration, 765
scopolamine, 819
sleep-inducing doses, 875
stress, 491
tolerance, 381
Monoamine levels, 1039
caffeine
5,7-dihydroxytryptamine (5,7-DHT)
6-hydroxydopamine (6-OHDA)
locomotor activity
Monoamines, 757
amphetamine, fixed interval
morphine, fixed interval
prenatal morphine
Morphiceptin, 1461
inhibition and facilitation
lordosis
naloxazone
naloxone
Morphine

amphetamine, 1739
analgesia, 319
caudate nucleus, 1739
conditioned taste aversion, 71
convulsions, 1241
corticosterone, 911
cyclazocine, 479
diazepam, 319
diurnal rhythm, 911
drug differences, 1739
drug discrimination, 479
drug history, 479
drug interactions, 849
eating, 911, 931
EEG discharges, 1241
formalin test, 319
hamsters, 849
hyperactivity, 849
hypoxia, 1687
lesions, 6-hydroxydopamine (6-OHDA), 931
lesions, PVN electrolytic, 931
lesions, visual cortex, 71
locomotor activity, 1687
macronutrient selection, 931
naloxone, 849, 1241
neurotransmitter metabolism, 1687
penicillin, 1241
pigeons, 479
place conditioning, 71
rabbits, 1241
septal nucleus, 1739
stress, 319

Morphine analgesia
antidepressants, 155
desipramine, 155
drug interactions, 1721
jump test, 1721
naloxonazine, 1721
opioid receptors, 155
tail flick, 1721

Morphine discrimination, 597
color tracking procedure
drug interactions
pigeons

Morphine, fixed interval, 757
amphetamine, fixed interval
monoamines
prenatal morphine

Morphine withdrawal, 151
microwave irradiation
naloxone
wet dog shakes

Mortality, 869
activity stress
drinking
ethanol
ulcer development

Motivation, 259
eating
experience
hypokinesia
pimozide

Motor coordination
L-ascorbic acid, 543
chronic administration, 1805
ethanol-induced CNS depression, 543
ethanol-induced hypnosis, 543
functional tolerance, 1805
phenobarbital, 1805

Motor habituation, 1679
bin analysis
DHT model
locomotor activity

Motor impairment, 1115
adenylate cyclase
ethanol intoxication
genetic breeding
Na+K-ATPase
5′-nucleotidase

Mouse-killing behavior, 657
GABAmimetic drugs
olfactory bulb

MSH-release inhibiting factor-1 (MIF-1), 1785
catalepsy
haloperidol
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1)

Multiple amphetamine schedule, 449
dopaminergic function
locomotor activity
perinatal undernutrition
stereotypy

Multiple microinjections, 1809
cannula
construction
implantation

Multivariate statistics, 291
apomorphine
autoreceptors
locomotor activity

Muricide
anticholinergics, 135
antidepressants, 135
brain catecholamines, 1715
desipramine, 1715
olfactory bulbectomy, 1715

Muscarinic antagonists, 865
anticholinergic sensitivity
drug tolerance
exercise, chronic

Muscimol, 1189
dopamine
feeding response
nucleus accumbens
nucleus raphe dorsalis

Na+K-ATPase, 1115
adenylate cyclase
ethanol intoxication
genetic breeding
motor impairment
5′-nucleotidase

Naloxazone, 1461
inhibition and facilitation
lordosis
morphiceptin
naloxone

Naloxonazine, 1721
drug interactions
jump test
morphine analgesia
tail flick

Naloxone
apomorphine, 1779
brain self-stimulation, 439
convulsions, 1241
dehydration, 1129
dogs, 1129
drinking, 1129
drug interactions, 849
drug-opiate interaction, 1779
EEG discharges, 1241
grooming, 1779
hamsters, 849
hyperactivity, 849
inhibition and facilitation, 1461
lordosis, 1461
microwave irradiation, 151
morphiceptin, 1461
morphine, 849, 1241
morphine withdrawal, 151
naloxazone, 1461
nose-poke, 439
opiates, 1779
opioid-receptor blockade, 439
penicillin, 1241
rabbits, 1241
stretching, 1779
vasopressin levels, 1129
wet dog shakes, 151
yawning, 1779

Naltrexone, 309
human studies, females
hypothalamic-anterior-pituitary axis
menstruation

Narcotic reactions, 895
chlordiazepoxide
drug comparisons
ethanol
phenobarbital
selective breeding
sleep time
thiopental

Natriuresis, 1503
diuresis
drinking
sodium appetite
vanadate

Nausea, 159
cigarette smoking
pituitary hormone release

Negative automaintenance, 555
anticonvulsive effects
automaintenance
pigeons

Negative reinforcer, 905
atropine
caudate-putamen
learning and retention
passive avoidance
retrograde amnesia

Neonatal clomipramine, 1451
alcohol deprivation
strain differences
voluntary alcohol consumption

Neonatal development, 537
locomotor activity
serotonergic agonists
serotonergic antagonists

Neonatal dopamine depletion, 1101
catecholamine terminals
intrinsic neurons
self-stimulation
ventral tegmentum

Neonatal manipulation, 1175
hypothalamus
serotonin levels
sexual activity

Neonatal monosodium glutamate, 1343
β-endorphin
ethanol
hypothalamic arcuate nucleus
neurosensitivity

Neurochemical effects, 341
  behavioral effects
  drug interactions
  lysergic acid diethylamide-25 (LSD-25)
Neuroleptics, atypical, 1639
  apomorphine
  dopamine receptors
  hypomotility
  stereotyped behaviors
Neuronal heterogeneity, 1403
  hippocampal circuitry
  metaphit
  phencyclidine (PCP)
Neuronal sensitivity, 949
  calcium
  ethanol
  selective breeding
Neuronal systems, 1429
  cocaine
  intracranial self-administration
  medial prefrontal cortex
Neuronal uptake, 55
  ethanol
  inbred strains
  pentobarbital
Neurosensitivity, 1343
  β-endorphin
  ethanol
  hypothalamic arcuate nucleus
  neonatal monosodium glutamate
Neurotensin
  antinociception, 425
  dopamine agonists, 425, 1195
  dopamine antagonists, 425
  eating, 1195
  hot plate, 425
Neurotoxic agents, 107
  lesions, kainic acid
  lesions, lateral septum
  psychoneuroendocrine functions
Neurotoxicity, 1301
  baclofen
  drug interactions
  in vivo
  phenytoin
  progabide
  seizures
Neurotransmitter metabolism, 1687
  hypoxia
  locomotor activity
  morphine
Nicotine
  amphetamine, 883
  brown adipose tissue (BAT), 1605
  catecholamines, 99
  cigarettes, 171
  classical conditioning, 883
  conditioned drug effects, 883
  conditioned taste aversion, 567
  conditioned taste avoidance, 883
  deprivation, 171
  diallel cross, 743
  dose-response relationship, 769
  drug differences, 1767
  drug discrimination, 769
  eating, 1605
  electrocortical activity, 99
  ethanol, 769
  genetic analysis, 743
  hamsters, 567
  human studies, 171
  lithium, 883
  mecamylamine, 1767
  nicotinic effects, 1767
  open field, 743
  reinforcement, 171
  saccharin, 567
  strain differences, 1767
  thermogenesis, 1605
Nicotinic effects, 1767
  drug differences
  mecamylamine
  nicotine
  strain differences
Nicotinic receptors, 1509
  central aminergic mechanisms
  convulsions, nicotine induced
Nictitating membrane response, 1293
  classical conditioning
  lysergic acid diethylamide (LSD)
  rabbits
Nitrendipine, 417
  calcium antagonist binding
  dihydropyridine
  phencyclidine (PCP)
Nociception
  catecholaminergic pathways, 1441
  chronic pain, 49
  Freund's adjuvant, 49
  6-hydroxydopamine (6-OHDA), 1441
  inflammation, 49
  spinal cord, 1441
Noradrenaline depletion, 777
  N-[2-chloroethyl]-N-ethyl-2-bromo-benzyl-amine DSP4)
  hippocampal kindling
  limbic seizures
  wet dog shakes
Noradrenaline turnover, 115
  preshock experience
  sensitization
  stress
Norcocaine, 305
  α-adrenoceptors
  dopamine receptors
  locomotor activity
Norepinephrine, 1015
  drug interactions
  lordosis
  medial preoptic area
Norepinephrine concentration, 1397
  β-adrenergic receptors
  electrophysiological responsiveness
  hippocampus
  lesions, DSP4
Norepinephrine levels, 1801
  acetylcholine levels
  arecoline
Norepinephrine metabolism
  catecholamine metabolism, 229
  catecholamines, 299
  diet-induced obesity, 299
  dopamine turnover, 299
  water imbalance, 229
Nose-poke, 439
  brain self-stimulation
  naloxone
  opioid-receptor blockade
5′-Nucleotidase, 1115
  adenylate cyclase
  ethanol intoxication
  genetic breeding
  motor impairment
  Na+K-ATPase
Nucleus accumbens
  dopamine, 223, 1189
  feeding response, 1189
  locomotor activity, 223
  muscimol, 1189
  nucleus raphe dorsalis, 1189
  striatum, 223
Nucleus raphe dorsalis, 1189
  dopamine
  feeding response
  muscimol
  nucleus accumbens

Olfactory bulb, 657
  GABAmimetic drugs
  mouse-killing behavior
Olfactory bulbectomy
  avoidance, 199
  brain catecholamines, 1715
  desipramine, 1715
  fluoxetine, 199
  muricide, 1715
  Y-maze, 199
  zimeldine, 199
Open field
  acetyl-l-carnitine, 1393
  active avoidance behavior, 1393
  brain serotonin metabolism, 1611
  diallel cross, 743
  dietary fat, 1775
  β-endorphin, 1235
  genetic analysis, 743
  6-hydroxydopamine (6-OHDA), 15
  hypertension, 15
  learning/memory tests, 1611
  locomotor activity, 15
  lordosis, 1235
  nicotine, 743
  opioid receptors, 1235
  pain threshold, 1775
  passive avoidance behavior, 1393
  portacaval shunt, 1611
  somatosensory reactivity, 1611
  thermoregulation, 1775
Open field behavior
  adrenocorticotropic hormone (ACTH), 1253
  anxiety, 1733
  hippocampus, 1733
  histidyl-proline, 1229
  indole-aldehyde adduct, 1733
  locomotor activity, 1229
  medial septum, 1253
  self-stimulation, 1253
  tetrahydro-β-carboline (THBC), 1733
  visual discrimination, 1229
Opiate receptors, 61
  locomotor activity
  mesolimbic system
Opiates, 1779
  apomorphine
  drug-opiate interaction
  grooming
  naloxone
  stretching
  yawning
Opioid effects, 1761
  body temperature
  route of administration
Opioid-hallucinogen interactions, 401
  N,N-dimethyltryptamine (DMT)

fixed ratio schedule
lysergic acid diethylamide (LSD)
Opioid kappa receptors, 861
backwards walking
bremazocine
psychomimetic activity
Opioid-receptor blockade, 439
brain self-stimulation
naloxone
nose-poke
Opioid receptors
antidepressants, 155
desipramine, 155
drug interactions, 1629
β-endorphin, 1235
lordosis, 1235
morphine analgesia, 155
open field, 1235
phencyclidine (PCP), 1629
stereotypy, 1629
Opioids
analgesic action, 1247
choice paradigm, 507
drinking, 833
drug interactions, 561
eating, 561, 833
β-endorphin, 507
oral sensory function, 833
quantitative differences, 1247
slugs, 561
sociosexual proclivity, 507
taste preference, 833
Oral self-administration, 1417
ethanol
inbred strains
Oral sensory function, 833
drinking
eating
opioids
taste preference
Organophosphates
atropine, 845
behavioral tolerance, 845
cholinesterase inhibition, 737
conditioned taste aversion, 737
drug interactions, 845
soman, 845
Orienting reflex, 677
classical conditioning
heart rate
lysergic acid diethylamide (LSD)
pizotifen (BC-105)
rabbits
xylamidine
Overtraining reversal effect, 1539
amphetamine
reversal learning
Oxytocin, 1185
dopamine neurotransmission
grooming
lesions, nucleus accumbens

Pain threshold, 1775
dietary fat
open field
thermoregulation
Palatability, 217
chlordiazepoxide
ingestion
Passive avoidance
active avoidance, 631, 687
aniracetam, 1123
atropine, 905
catecholamines, 631
caudate-putamen, 905
cerebral embolization, 687, 1729
choline acetyltransferase, 1729
drug interactions, 631
flinch jump threshold, 687
Hydergine®, 1123
hypoxia, 1123
learning and retention, 905
memory, 1729
memory impairment, 687
memory retention, 631
negative reinforcer, 905
protein synthesis inhibitors, 631
scopolamine, 1123
vinpocetine, 1123
Passive avoidance behavior, 1393
acetyl-l-carnitine
active avoidance behavior
open field
Penicillin, 1241
convulsions
EEG discharges
morphine
naloxone
rabbits
Pentobarbital
d-amphetamine, 1305
barbital, 801
benzodiazepine antagonists, 999
chlordiazepoxide, 93, 999
cross-tolerance, 801
diazepam, 1071
dogs, 1071
drug discrimination, 999, 1305
drug interactions, 999, 1071, 1305
ethanol, 55, 93, 801, 1305
fixed interval/fixed ratio schedule, 1071
inbred strains, 55
neuronal uptake, 55
pigeons, 1305
tolerance, 93, 801
Pentobarbital stimulation, 1215
[^{3}H]flunitrazepam binding
inhibitory effect
kynurenine
quinolinic acid
Peptide
adrenocorticotropic hormone ($ACTH_{1-24}$), 1253
adrenocorticotropic hormone ($ACTH_{4-10}$), 1253
adrenocorticotropic hormone ([D-Phe^7]$ACTH_{4-10}$), 1253
angiotensin II, 721, 1573
calcitonin, 1203
cholecystokinin-octapeptide (CCK-8), 983
delta sleep-inducing peptide (DSIP), 889, 1797
β-endorphin, 507, 1235
follicle stimulating hormone (FSH), 1749
histidyl-proline, 1229
luteinizing hormone (LH), 1749
luteinizing hormone-releasing hormone (LHRH), 433
melatonin, 1497
morphiceptin, 1461
MSH-release inhibiting factor-1 (MIF-1), 1785
neurotensin, 425, 1195
Org 2766, 1253
oxytocin, 1185
somatostatin, 1703
thyrotropin-releasing hormone (TRH), 1263, 1423, 1593, 1817
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 1785
Perforant path stimulation, 85
aminophylline
dentate gyrus
kindling
Performance assessment battery, 1111
atropine
human studies
psychometrics
Perinatal undernutrition, 449
dopaminergic function
locomotor activity
multiple amphetamine schedule
stereotypy
Peripheral 5-HT, 1133
eating rate
feeding bouts
microstructural analysis
satiety
Peripheral type benzodiazepine receptors, 1673
inescapable shock
Ro 5-4864 binding
stress
Perseveration, 323
diazepam
response invigoration
stress
swim task
Personal computer, 1789
infrared beam device
Pharmacogenetics, 1095
etonitazene
food deprivation
strain differences
Pharmacokinetics, 485
ethanol
intersubject variability
monkeys
Phencyclidine (PCP)
calcium antagonist binding, 417
dihydropyridine, 417
drug interactions, 1629
excitatory amino acids, 23
hippocampal circuitry, 1403
metaphit, 1403
2-methyl-3,3-diphenyl-3-propranolamine (2-MDP), 23
neuronal heterogeneity, 1403
nitrendipine, 417
opioid receptors, 1629
radial maze, 187
reserpine pretreatment, 1275
SKF-10,047, 187
stereotypy, 1629
verapamil, 187
wet dog shakes, 1275
Phencyclidine derivatives, 127
route of administration
Phenobarbital
adrenalectomy, 1651
chlordiazepoxide, 895
chronic administration, 1805
drug comparisons, 895

ethanol, 895
functional tolerance, 1805
glucocorticoids, 1651
hypnotic response, 1651
hypothermia, 1651
motor coordination, 1805
narcotic reactions, 895
selective breeding, 895
sleep time, 895
thiopental, 895
β-Phenylethanolamine, 1547
drug discrimination
fenfluramine
β-phenylethylamine
β-Phenylethylamine
catechol-O-methyltransferase, 1141
drug discrimination, 1547
fenfluramine, 1547
gerbils, 1141
β-phenylethanolamine, 1547
red blood cell enzymes, 1141
Phenylpropanolamine
d-amphetamine, 1665
BAT thermogenesis, 605
body weight, 605
drinking, 605
drug discrimination, 1665
eating, 605
human studies, 1665
mazindol, 1665
subjective effects, 1665
Phenytoin, 1301
baclofen
drug interactions
in vivo
neurotoxicity
progabide
seizures
Pigeons
d-amphetamine, 1305
anticonvulsant drugs, 1583
anticonvulsive effects, 555
automaintenance, 555
benzodiazepine receptors, 121
buspirone, 751
color tracking procedure, 597
cyclazocine, 479
dopamine, 751
drug discrimination, 479, 1305
drug history, 479
drug interactions, 597, 1305
ethanol, 1305
inosine, 121
morphine, 479
morphine discrimination, 597
negative automaintenance, 555
pentobarbital, 1305
punished behavior, 121, 751
repeated acquisition procedure, 1583
tolerance, 1583
Pimozide
brain stimulation reward, 1577
conditioned taste aversion, 1527
eating, 259
experience, 259
hypokinesia, 259
incentive contrasts, 1577
motivation, 259
saccharin, 1527
Piribedil, 531
cocaine
dopamine receptors
rhesus monkeys
self-administration
Pituitary hormone release, 159
cigarette smoking
nausea
Pituitary-thyroid axis, 1817
body weight
food intake
thyrotropin-releasing hormone (TRH)
Pizotifen (BC-105), 677
classical conditioning
heart rate
lysergic acid diethylamide (LSD)
orienting reflex
rabbits
xylamidine
Place conditioning, 71
conditioned taste aversion
lesions, visual cortex
morphine
Place preference, 1793
amphetamine
cocaine
drug sensitivity
housing conditions
Plasma angiotensin II and III, 813
ethanol treatment
hypovolemia
receptor binding
Plasma corticosterone
β-adrenoceptor desensitization, 991
age differences, 991
handling, 1151
hypothalamic norepinephrine, 1151
social isolation, 1151
stress, 991
stressors, acute and chronic, 1151
Platelet rich plasma, 1219
endogenous β-carboline
harmanes
porphyria
Play behavior, 455
amphetamine
juvenile rats
locomotor activity
Play fighting, 1157
cholinergic influences
social development
Polyamines, 1543
adrenocorticotropic hormone (ACTH)
brain lipase
Porphyria, 1219
endogenous β-carboline
harmanes
platelet rich plasma
Portacaval shunt
behavioral effects, 1323
brain levels, amino acids, 1323
brain levels, transmitter amines, 1323
brain serotonin metabolism, 1611
dietary histidine loading, 1323
dietary methionine loading, 1323
learning/memory tests, 1611
open field, 1611
somatosensory reactivity, 1611
Positively-reinforced learning, 715
auto-shaping
cholinergic activity
striatum
Post-learning effects, 1813
ethanol
memory
stimulus control
water-finding task
Postnatal exposure, lactation, 1695
caffeine
developmental reflexes
locomotor activity
taste preference
Potentiation
adenosine receptors, 429
cocaine-caffeine interaction, 761
dose-dependent effects, 761
locomotor stimulant activity, 761
sweeteners, 429
taste, 429
Preferred ambient temperature, 1147
behavioral thermoregulation
sodium pentobarbital
temperature gradient
Pregnancy
animal models, 625
behavioral pathogenesis, 165
drinking fluid with ethanol, 625
dysmorphogenesis, 165
Fetal Alcohol Syndrome, 165, 625
Prenatal drug exposure, 1383
antiepileptic drugs
seizure susceptibility
Prenatal morphine, 757
amphetamine, fixed interval
monoamines
morphine, fixed interval
Prenatal stress, 1377
development
locomotor activity
serotonergic neurons
Preshock experience, 115
noradrenaline turnover
sensitization
stress
Primate model, 381
drug comparisons
hallucinogens
limb jerk
monkeys
primate social behavior
tolerance
Primate social behavior, 381
drug comparisons
hallucinogens
limb jerk
monkeys
primate model
tolerance
Progabide, 1301
baclofen
drug interactions
in vivo
neurotoxicity
phenytoin
seizures
Prolactin, 67
conditioned avoidance
lergotrile
Prolactin secretion, 1445
convulsions, post-decapitation
isofloxythepin
zotepine
Protein metabolism, 143
amino acid transport
blood-brain
long term consequences
Protein synthesis inhibitors, 631

active avoidance
catecholamines
drug interactions
memory retention
passive avoidance
Proximity, 1025
d-amphetamine
grooming
social behavior
stumptail macaques
Psychedelic effects, 407
hallucinogen research
lysergic acid diethylamide (LSD)
Psychometrics, 1111
atropine
human studies
performance assessment battery
Psychomimetic activity, 861
backwards walking
bremazocine
opioid kappa receptors
Psychomotor stimulation, 581
aggression
anticholinergic agents
cats
Psychoneuroendocrine functions, 107
lesions, lateral septum
lesions, kainic acid
neurotoxic agents
Punished behavior
benzodiazepine receptors, 121
buspirone, 751
dopamine, 751
inosine, 121
pigeons, 121, 751
Push-pull cannula, 147
conscious animals

Quantitative differences, 1247
analgesic action
opioids
Quinolinic acid, 1215
[^{3}H]flunitrazepam binding
inhibitory effect
kynurenine
pentobarbital stimulation
Quinpirole, 721
angiotensin II
drinking
drug interactions
hypertonic saline
isoproterenol

R1881, 285
androgens
sexual orientation
Rabbits
brain water content, 785
central venous pressure, 785
classical conditioning, 677, 1293
convulsions, 1241
EEG discharges, 1241
fentanyl, 785
heart rate, 677
hippocampus, 183
intracranial pressure, 785
lesions, parieto-occipital cortex, 785
lysergic acid diethylamide (LSD), 183, 677, 1293
morphine, 1241
naloxone, 1241
nictitating membrane response, 1293
orienting reflex, 677
pizotifen (BC-105), 677
systolic arterial pressure, 785
theta rhythms, 183
Radial maze, 187
phencyclidine (PCP)
SKF-10,047
verapamil
Raphe unit activity, 351
cats
drug interactions
hallucinogens
serotonin receptors
Receptor binding, 813
ethanol treatment
hypovolemia
plasma angiotensin II and III
Red blood cell enzymes, 1141
catechol-O-methyltransferase
gerbils
β-phenylethylamine
Reinforcement
cigarettes, 171
conditioned place aversion, 1369
deprivation, 171
ethanol self-administration, 1369
human studies, 171
nicotine, 171
REM sleep deprivation, 809
dopamine receptors
^{3}H-spiroperidol binding
striatum
Repeated acquisition procedure, 1583
anticonvulsant drugs
pigeons
tolerance
Reserpine, 1457
ACh levels
amnesia
syrosingopine
Reserpine pretreatment, 1275
phencyclidine (PCP)
wet dog shakes
Respiratory quotient, 647
dextrofenfluramine
locomotor activity
total energy expenditure
Response speed, 503
age differences
amphetamine
illumination
methylphenidate
squirrel monkeys
Response invigoration, 323
diazepam
perseveration
stress
swim task
Retrograde amnesia, 905
atropine
caudate-putamen
learning and retention
negative reinforcer
Reversal learning, 1539
amphetamine
overtraining reversal effect
Rhesus monkeys
anxiolytic responding, 855
cocaine, 531
dopamine receptors, 531
piribedil, 531
Ro 15-1788, 855
self-administration, 531, 855
Righting reflex, 1263
drug interactions
ethanol
medial septum
thyrotropin-releasing hormone (TRH)
Righting response
benzodiazepine antagonists, 963
diazepam, 963
drug interactions, 963
ethanol, 967
hamsters, 967
hereditary cardiomyopathy, 967
monkey/pigeon comparisons, 963
sex differences, 967
sodium excretion, 967
strain differences, 967
water excretion, 967
Rigid dopamine analogues, 253
lesions, 6-hydroxydopamine (6-OHDA)
stereotypy
striatal response
Ro 5-4864, 193
benzodiazepine antagonists
intracranial self-stimulation
Ro 5-4864 binding, 1673
inescapable shock
peripheral type benzodiazepine receptors
stress
Ro 15-1788, 855
anxiolytic responding
rhesus monkeys
self-administration
Route of administration
d-amphetamine, 765
benzodiazepines, 1703
body temperature, 1761
CGS 8216, 1703
cocaine, 765
dose response, 247
drinking, 247
drug discrimination, 765
eating, 247
opioid effects, 1761
phencyclidine derivatives, 127
satietin, 247

Saccharin
conditioned taste aversion, 567, 1527
hamsters, 567
nicotine, 567
pimozide, 1527
Salbutamol, 177
β-adrenoreceptors
clenbuterol
learned-helplessness
shuttle-box
Sarin, 941
ChE inhibition
diisopropylphosphorofluoridate (DFP)
locomotor activity
soman
Satietin, 247
dose response
drinking
eating
route of administration

Satiety
aversion, 5
calcitonin gene-related peptide (CGRP), 5
eating rate, 1133
feeding bouts, 1133
microstructural analysis, 1133
peripheral 5-HT, 1133
Scopolamine
alternation, 1353
aniracetam, 1123
Hamilton search task, 819
Hydergine®, 1123
hypoxia, 1123
lead exposure, 819
learning, 1635
lesions, basal forebrain, 1353
lesions, septum, 1635
memory, 819, 1353
methylscopolamine, 1635
monkeys, 819
passive avoidance, 1123
shock escape, 1635
spatial discrimination, 1353
vincamine, 1123
vinpocetine, 1123
Seizure susceptibility, 1383
antiepileptic drugs
prenatal drug exposure
Seizures
aminophylline, 1599
amphetamine, 1617
amygdala, 1599
baclofen, 1301
drug interactions, 1301
GABA receptors, 665
inhibition, 1599
in vivo, 1301
kindling, 1599
learning, 1617
medial prefrontal cortex, 1617
neurotoxicity, 1301
phenytoin, 1301
progabide, 1301
self-stimulation, 1617
strain differences, 665
Selective breeding
calcium, 949
chlordiazepoxide, 895
drug comparisons, 895
ethanol, 895, 949
narcotic reactions, 895
neuronal sensitivity, 949
phenobarbital, 895
sleep time, 895
thiopental, 895
Self-administration
anxiolytic responding, 855
cocaine, 531
dopamine receptors, 531
piribedil, 531
rhesus monkeys, 531, 855
Ro 15-1788, 855
Self-stimulation
adrenocorticotropic hormone (ACTH), 1253
amphetamine, 1617
brain stimulation reward, 919
catecholamine terminals, 1101
D_1 receptor, 919
D_2 receptor, 919
dopamine receptor blockade, 919
intrinsic neurons, 1101
learning, 1617
medial prefrontal cortex, 1617
medial septum, 1253
neonatal dopamine depletion, 1101
open field behavior, 1253
seizures, 1617
ventral tegmentum, 1101
Sensitization, 115
noradrenaline turnover
preshock experience
stress
Septal nucleus, 1739
amphetamine
caudate nucleus
drug differences
locomotor activity
morphine
Serotonergic agonists, 537
locomotor activity
neonatal development
serotonergic antagonists
Serotonergic antagonists, 537
locomotor activity
neonatal development
serotonergic agonists
Serotonergic function, 1467
anxiety
5-hydroxytryptamine (5-HT)
Serotonergic mechanisms, 701
anxiety
buspirone
conflict
gepirone
lesions, 5,7-dihydroxytryptamine (5,7-DHT)
Serotonergic mediation, 1203
central nervous system (CNS)
drug discrimination
tetrahydro-β-carboline (THBC)
Serotonergic neuronal systems, 359
hallucinogens
lysergic acid diethylamide (LSD)
Serotonergic neurons
anxiety, 1471
anxiolytic activity, 1471
benzodiazepines, 1471
development, 1377
locomotor activity, 1377
prenatal stress, 1377
waiting capacity, 1471
Serotonergic system, 955
5,7-dihydroxytryptamine (5,7-DHT)
ethanol tolerance
Serotonin, 1623
animal hypnosis
chickens
tonic immobility
Serotonin levels, 1175
hypothalamus
neonatal manipulation
sexual activity
Serotonin metabolism, 445
calcium
depression
learned helplessness
Serotonin receptors, 351
cats
drug interactions
hallucinogens
raphe unit activity
Serotonin$_2$-receptors, 469
caerulein
dopamine$_2$-receptors
exploration
Serotonin uptake, 281
p-chloroamphetamine
enantiomers
fluoxetine
Sex differences
caffeine, 1555
ethanol, 967
food deprivation, 1555
hamsters, 967
hereditary cardiomyopathy, 967
righting response, 967
sodium excretion, 967
strain differences, 967
two-bottle preference, 1555
water excretion, 967
Sexual activity, 1175
hypothalamus
neonatal manipulation
serotonin levels
Sexual behavior, male rats, 1065
GABAergic transmission
Sexual orientation, 285
androgens
R1881
Shock escape, 1635
learning
lesions, septum
methylscopolamine
scopolamine
Shuttle-box, 177
β-adrenoreceptors
clenbuterol
learned-helplessness
salbutamol
SKF-10,047, 187
phencyclidine (PCP)
radial maze
verapamil
Sleep, 613
α-adrenoceptor blockade
wakefulness
Sleep factors, 889
delta sleep-inducing peptide (DSIP)
structure-activity relationship
Sleep-inducing doses, 875
hangover effects
hypnotics
monkeys
Sleep time, 895
chlordiazepoxide
drug comparisons
ethanol
narcotic reactions
phenobarbital
selective breeding
thiopental
Slugs, 561
drug interactions
eating
opioids
Smoke absorption, 587
cigarette smoke yields
human studies
inhalation volumes
Social behavior, 1025
d-amphetamine
grooming
proximity
Social behavior, male rats, 1645

aggression
benzodiazepines
β-carboline
Social development, 1157
cholinergic influences
play fighting
Social isolation, 1151
handling
hypothalamic norepinephrine
plasma
stressors, acute and chronic
Sociosexual proclivity, 507
choice paradigm
β-endorphin
opioids
Sodium appetite, 1503
diuresis
drinking
natriuresis
vanadate
Sodium excretion, 967
ethanol
hamsters
hereditary cardiomyopathy
righting response
sex differences
strain differences
water excretion
Sodium intake, 1167
hypertension
strain differences
voluntary ethanol consumption
Sodium pentobarbital, 1147
behavioral thermoregulation
preferred ambient temperature
temperature gradient
Sodium valproate, 823
β-carboline carboxylic acid ethyl ester (β-CCE)
convulsions, drug-induced
diazepam
Soman
atropine, 845
behavioral tolerance, 845
ChE inhibition, 941
diisopropylphosphorofluoridate (DFP), 941
drug interactions, 845
locomotor activity, 941
organophosphates, 845
sarin, 941
Somatosensory reactivity, 1611
brain serotonin metabolism
learning/memory tests
open field
portacaval shunt
Somatostatin, 1703
cysteamine
dopamine-mediated behavior
locomotor activity
stereotypy
striatum
Spatial discrimination, 1353
alternation
lesions, basal forebrain
memory
scopolamine
Spinal cord, 1441
catecholaminergic pathways
6-hydroxydopamine (6-OHDA)
nociception
Spinal reflex, 1083
cross-tolerance
tail flick
tolerance, learned
tolerance, pharmacologically-induced
^{3}H-Spiroperidol binding, 809
dopamine receptors
REM sleep deprivation
striatum
Spontaneous alternation, 519
central cholinergic system
ethanol
memory dysfunction
Spontaneous hypertensive rats, 1797
delta sleep-inducing peptide (DSIP)
stress
Spontaneous motor activity
conditioned avoidance response, 433
drug interactions, 433
ethanol, 617
head shaking, 433
low-dose ethanol effects, 617
luteinizing hormone-releasing hormone (LHRH), 433
strain differences, 617
Squirrel monkeys, 503
age differences
amphetamine
illumination
methylphenidate
Stereotyped behavior
amphetamine, 1329
apomorphine, 1639
dopamine receptors, 1639
dopamine release, drug induced, 1755
hypomotility, 1639
intracerebral dialysis, 1755
locomotor activity, 1755
neuroleptics, atypical, 1639
strain differences, 1329
Stereotypy
cysteamine, 1703
D_2 receptors, 1829
dopamine-mediated behavior, 1703
dopaminergic function, 449
drug interactions, 1629
lesions, 6-hydroxydopamine (6-OHDA), 253
lesions, N-methyl-D-aspartate, 1829
lesions, prefrontal cortex, 1829
locomotor activity, 449, 1703, 1829
multiple amphetamine schedule, 449
opioid receptors, 1629
perinatal undernutrition, 449
phencyclidine (PCP), 1629
rigid dopamine analogues, 253
somatostatin, 1703
striatal response, 253
striatum, 1703
Stimulus control, 1813
ethanol
memory
post-learning effects
water-finding task
Stimulus generalization, 43
discrimination
1-(3-trifluoromethylphenyl)piperazine (TFMPP)
Stimulus properties, 1161
cathinone
drug discrimination
isomers
Strain differences
alcohol deprivation, 1451
alcohol preference, 879
amphetamine, 1329
depolarization-dependent calcium levels, 1137
diisopropylfluorophosphate (DFP), 1077
drug differences, 1767
emotional reactivity, 879
ethanol, 617, 967
ethanol sensitivity, 1137
etonitazene, 1095
food deprivation, 1095
GABA receptors, 665
hamsters, 967
hereditary cardiomyopathy, 967
hypertension, 1167
hypothermia, 1077
locomotor activity, 1077
low-dose ethanol effects, 617
mecamylamine, 1767
neonatal clomipramine, 1451
nicotine, 1767
nicotinic effects, 1767
pharmacogenetics, 1095
righting response, 967
seizures, 665
sex differences, 967
sodium excretion, 967
sodium intake, 1167
spontaneous motor activity, 617
stereotyped behavior, 1329
voluntary alcohol consumption, 1451
voluntary ethanol consumption, 1167
water excretion, 967
Stress
adrenergic receptor changes, 1587
β-adrenoceptor desensitization, 991
age differences, 991
alcohol consumption, 271
analgesia, 319
brain histamine regulation, 513
conflict, 271
delta sleep-inducing peptide (DSIP), 1797
diazepam, 319, 323, 513
dopamine turnover, 79
drinking, 491
eating, 491
ethanol, 491
food deprivation, 271
foot shock, 1587
formalin test, 319
5-HT turnover, 79
hypothermia, 79
inescapable shock, 1673
monkeys, 491
morphine, 319
noradrenaline turnover, 115
peripheral type benzodiazepine receptors, 1673
perseveration, 323
plasma corticosterone, 991
preshock experience, 115
response invigoration, 323
Ro 5-4864 binding, 1673
sensitization, 115
spontaneous hypertensive rats, 1797
swim test, 323
Stress, chronic, 1361
antidepressants
locomotor activity

Stress, mental, 1521
human studies
urinary monoamine metabolites
Stressors, acute and chronic, 1151
handling
hypothalamic norepinephrine
plasma corticosterone
social isolation
Stretching, 1779
apomorphine
drug-opiate interaction
grooming
naloxone
opiates
yawning
Striatal concentrations, 795
bupropion
dihydroxyphenylacetic acid (DOPAC)
dopamine
locomotor activity
Striatal response, 253
lesions, 6-hydroxydopamine (6-OHDA)
rigid dopamine analogues
stereotypy
Striatum
auto-shaping, 715
cholinergic activity, 715
cysteamine, 1703
dopamine, 223
dopamine-mediated behavior, 1703
dopamine receptors, 809
locomotor activity, 223, 1703
nucleus accumbens, 223
positively-reinforced learning, 715
REM sleep deprivation, 809
somatostatin, 1703
^{3}H-spiroperidol binding, 809
stereotypy, 1703
Stroke, 315
drug interactions
gerbils
survival effect
Structure-activity relationship
delta sleep-inducing peptide (DSIP), 889
hallucinogens, 335
molecular structure, 335
sleep factors, 889
tryptamines, 335
Stumptail macaques, 1025
d-amphetamine
grooming
proximity
social behavior
Subjective effects
d-amphetamine, 1665
behavioral effects, 1749
drug discrimination, 1665
hormone levels, 1749
human studies, 1665
human studies, males, 1749
marijuana, 1749
mazindol, 1665
phenylpropanolamine, 1665
Survival effect, 315
drug interactions
gerbils
stroke
Sweeteners, 429
adenosine receptors
potentiation
taste
Swim task, 323
diazepam
perseveration
response invigoration
stress
Synaptosomal membranes, 1659
Ca^{++} uptake
calmodulin
ethanol
Syrosingopine, 1457
ACh levels
amnesia
reserpine
Systolic arterial pressure, 785
brain water content
central venous pressure
fentanyl
intracranial pressure
lesions, parieto-occipital cortex
rabbits

Tail flick
antinociception, 709
p-chloroamphetamine, 709
cross-tolerance, 1083
drug interactions, 1721
formalin test, 709
hot plate, 709
jump test, 1721
lesions, ascending serotonergic pathways, 709
morphine analgesia, 1721
naloxonazine, 1721
spinal reflex, 1083
tolerance, learned, 1083
tolerance, pharmacologically-induced, 1083
Tail-flick test, 27
dependence
dermorphine
withdrawal
Taste, 429
adenosine receptors
potentiation
sweeteners
Taste aversion, 975
hyperactivity
latent inhibition
methylazoxymethanol
microencephaly
Taste preference
caffeine, 1695
developmental reflexes, 1695
drinking, 833
eating, 833
locomotor activity, 1695
opioids, 833
oral sensory function, 833
postnatal exposure, lactation, 1695
Temperature gradient, 1147
behavioral thermoregulation
preferred ambient temperature
sodium pentobarbital
Tetrahydro-β-carboline (THBC)
anxiety, 1733
central nervous system (CNS), 1203
drug discrimination, 1203
hippocampus, 1733
indole-aldehyde adduct, 1733
open field behavior, 1733
serotonergic mediation, 1203
Thermogenesis, 1605
brown adipose tissue (BAT)
eating
nicotine
Thermoregulation, 1775
dietary fat
open field
pain threshold
Theta rhythms, 183
hippocampus
lysergic acid diethylamide (LSD)
rabbits
Thiopental, 895
chlordiazepoxide
drug comparisons
ethanol
narcotic effects
phenobarbital
selective breeding
sleep time
Thirst, 1825
dietary salt-loading
drinking
ethanol selection
Thyrotropin-releasing hormone (TRH)
acute vs. chronic effects, 1423
body weight, 1817
drug interactions, 1263
ethanol, 1263
food intake, 1817
jumping behavior, 1423
locomotor activity, 1423
medial septum, 1263
pituitary-thyroid axis, 1817
righting reflex, 1263
Toads, 1315
cerebral amino acids
feeding behavior
hyperosmotic environment
Tolerance
air blast stimulation, 1007
anticonvulsant drugs, 1583
anticonvulsant effects, 1007
barbital, 801
chlordiazepoxide, 93
chronic spinal dogs, 393
cross-tolerance, 801
drug comparisons, 381
ethanol, 93, 801
ethanol stimulating effect, 1225
GABAmimetics, 1007
genetics, 1225
gerbils, epilepsy prone, 1007
hallucinogens, 381, 393
limb jerk, 381
locomotor activity, 1225
monkeys, 381
pentobarbital, 93, 801
pigeons, 1583
primate model, 381
primate social behavior, 381
repeated acquisition procedure, 1583
tryptaminergic pathways, 393
Tolerance, learned, 1083
cross-tolerance
spinal reflex
tail flick
tolerance, pharmacologically-induced
Tolerance, pharmacologically-induced, 1083

cross-tolerance
spinal reflex
tail flick
tolerance, learned
Tonic immobility, 1623
animal hypnosis
chickens
serotonin
Total energy expenditure, 647
dextrofenfluramine
locomotor activity
respiratory quotient
1-(3-Trifluoromethylphenyl)piperazine (TFMPP), 43
discrimination
stimulus generalization
Tryptaminergic pathways, 393
chronic spinal dogs
hallucinogens
tolerance
Tryptamines, 335
hallucinogens
molecular structure
structure-activity relationship
L-Tryptophan, 1491
acute and chronic administration
diazepam
human studies, males
5-hydroxytryptamine (5-HT) function
^{3}H-imipramine binding
Two-bottle preference, 1555
caffeine
food deprivation
sex differences
Tyr-MSH-release inhibiting factor-1 (Tyr-MIF-1), 1785
catalepsy
haloperidol
MSH-release inhibiting factor-1 (MIF-1)

Ulcer development, 869
activity stress
drinking
ethanol
mortality
Ultrasonic isolation calls, 1263
benzodiazepine antagonists
benzodiazepine receptors
Unavoidable shock, 271
alcohol consumption
conflict
food deprivation
stress
Urinary monoamine metabolites, 1521
human studies
stress, mental

Vanadate, 1503
diuresis
drinking
natriuresis
sodium appetite
Vasopressin levels, 1129
dehydration
dogs
drinking
naloxone
Ventral tegmentum, 1101
catecholamine terminals
intrinsic neurons
neonatal dopamine depletion
self-stimulation
Ventromedial hypothalamus, 673
GABAergic neurotransmission
lordosis
Verapamil, 187
phencyclidine (PCP)
radial maze
SKF-10,047
Vincamine, 1123
aniracetam
Hydergine®
hypoxia
passive avoidance
scopolamine
vinpocetine
Vinpocetine, 1123
aniracetam
Hydergine®
hypoxia
passive avoidance
scopolamine
vincamine
Visual discrimination, 1229
histidyl-proline
locomotor activity
open field behavior
Voluntary ethanol consumption, 1167
hypertension
sodium intake
strain differences

Waiting capacity, 1471
anxiety
anxiolytic activity
benzodiazepines
serotonergic neurons
Wakefulness, 613
α-adrenoceptor blockade
sleep
Water excretion, 967
ethanol
hamsters
hereditary cardiomyopathy
righting response
sex differences
sodium excretion
strain differences
Water-finding task, 1813
ethanol
memory
post-learning effects
stimulus control
Water imbalance, 229
catecholamine metabolism
norepinephrine metabolism
Wet dog shakes
N-[2-chloroethyl]-N-ethyl-2-bromobenzyl-amine (DPS4), 777
hippocampal kindling, 777
limbic seizures, 777
microwave irradiation, 151
morphine withdrawal, 151
naloxone, 151
noradrenaline depletion, 777
phencyclidine (PCP), 1275
reserpine pretreatment, 1275
Withdrawal, 27
dependence
dermorphine
tail-flick test

Xylamidine, 677
classical conditioning
heart rate
lysergic acid diethylamide (LSD)
orienting reflex
pizotifen (BC-105)
rabbits

Yawning, 1779
apomorphine
drug-opiate interaction
grooming
naloxone
opiates
stretching
Y-maze, 199
avoidance
fluoxetine
olfactory bulbectomy
zimeldine

Zimeldine
avoidance, 199
conditioned taste aversion, 463
drinking suppression, 463
ethanol, 463
fluoxetine, 199
olfactory bulbectomy, 199
Y-maze, 199
Zotepine, 1445
convulsions, post-decapitation
isofloxythepin
prolactin secretion

AUTHOR INDEX

Abbott, F. V., 319, 1247
Abhold, R. H., 813
Adams, M. A., 33
Adler, M. W., 1761
Ahlenius, S., 1409
Ahluwalia, P., 1151
Alberti, M. H., 631
Albertson, T. E., 85, 1599
Alföldi, P., 889
Algeri, S., 991
Allikmets, L. H., 1, 469
Alloro, M. C., 1393
Alpern, H. P., 895
Amalric, M., 61
Amit, Z., 463, 1527, 1793
Anderson, E. G., 347
Anderson, G. D., 1561
Ando, K., 693
Anisman, H., 323, 1151
Antonian, L., 253
Araki, Y., 571
Arasteh, K., 445
Archer, T., 975
Azar, A. P., 931

Baddoo, P., 513
Baldwin, R. A., 1315
Barkemeyer, C. A., 1195
Barraco, R. A., 263
Barrett, J. E., 121, 751, 963
Barron, S., 165
Bartus, R. T., 1287
Basile, A. S., 1673
Bättig, K., 587
Baxter, C. F., 1315
Beart, P. M., 1829
Beatty, W. W., 1157
Beck, C. H. M., 1645
Becker, H. C., 1057
Beeker, T. G., 429
Beleslin, D. B., 329, 581, 1509, 1821
Bellinger, L. L., 247
Belmaker, R. H., 9
Bendotti, C., 1189
Bengtsson, F., 1611
Ben Horin, E., 1539
Beninger, R. J., 259, 1353
Bennett, E. L., 631
Beracochea, D., 519
Berettera, C., 1189
Berge, O.-G., 709, 1441
Bermúdez-Rattoni, F., 715
Bernard, P. S., 1703
Bero, L., 795
Berridge, K. C., 217
Beuthin, F. C., 211
Bex, F., 1573
Beyer, C., 673, 1065
Bhakthavatsalam, P., 911
Bierley, R. A., 1157
Bitran, D., 1047
Blake, J. C., 23
Blakely, E., 555, 1583
Bodnar, R. J., 1721
Boegman, R. J., 1353
Boldry, R., 223
Bolger, G. T., 417
Booth, J. V., 1623
Bortolotto, Z. A., 777
Bouchet, M. J., 497
Bowden, D. M., 485, 491
Bowman, R. E., 819
Boyer, J., 1543
Brandao, M. L., 497
Breese, G. R., 1269
Bridge, S., 1829
Brioni, J. D., 449
Broch, O. J., 709
Broekkamp, C. L. E., 1253
Brown, D. R., 49
Brown, H. A., 1457
Brown, O. M., 1457
Brueggemeier, R. W., 139
Bruinvels, J., 1219
Bryant, H. U., 899
Bullock, S. P., 549
Burch, J. B., 743
Burton, M. J., 1133
Buzzi, R., 587
Byrd, L. D., 1025

Caldwell, J. D., 1015, 1185
Calil, H. M., 809
Calvani, M., 1393
Canon, J., 875
Caplan, M. A., 271
Carlsson, A., 237
Carney, J. M., 865, 1281, 1333
Carroll, M. E., 1095
Carvell, T., 883
Cassone, M. C., 1801
Caton, T. M., 567
Cavalheiro, E. A., 777
Chait, L. D., 1665
Chang, Y., 223
Chiaraviglio, E., 1503
Chou, C. K., 151
Christensen, H. D., 1695
Christie, M. J., 1829
Church, J., 23
Chweh, A. Y., 1301
Ciesielski, L., 657
Clemens, L. G., 1015
Coggins, P. J., 1229
Cohen, E., 1329
Cohen, M. R., 1587
Cohen, R. M., 1587
Collins, A. C., 743, 1077, 1767
Collins, C., 323
Commissaris, R. L., 727
Cone, E. J., 1749
Continella, G., 1185, 1393
Cook, J. M., 963
Cooper, C. W., 1203
Cooper, S. J., 1645
Córdoba, N., 449
Cornell, K., 99
Coscina, D. V., 1775
Costa, L. G., 733, 737
Costantini, C., 991
Cotecchia, S., 991
Coupet, J., 253
Cowen, P. J., 1491
Cox, W. M., 1555
Crabbe, J. C., 1343
Crawley, J. N., 1673
Cristofaro, P., 309
Crocker, A. D., 1593
Crocker, J. M., 1593
Darnell, R. J., 727
DaVanzo, J. P., 135
Davies, S. N., 23
Davis, J. M., 381
Dean, R. L., 1287
De Blasi, A., 991
de Boer, S., 15
deFiebre, C. M., 1089
de Jong, W., 15
de Jonge, F. H., 285
Delay, E. R., 503
DeLong, R. E., 263
Del Real, C., 165
de Maria, G., 183
Denbow, D. M., 39
DeNoble, V. J., 1123
De Vry, J., 999
Diaz, C., 429
Diaz-Veliz, G., 433
Dill, R. E., 781
Dinish, J. L., 1573
Di Scala, G., 497
Dixon, L. M., 1775
Dluzen, D. E., 147
Dole, J. W., 1315
Domino, E. F., 401
Dorris, R. L., 781
Dorsa, D. M., 1343
Drago, F., 425, 1185, 1393
Driscoll, P., 1329
Drugan, R. C., 1673
Dudley, C. A., 507
Dunwiddie, T. V., 1397
Durkin, T. P., 519
Dworkin, S. I., 1429
Dwoskin, L. P., 341

Edwardson, J. A., 1229
Ehlers, C. L., 1813
Eisenhofer, G., 1825
Eison, A. S., 701
Eison, M. S., 701
El-Atrash, S., 49
El-Defrawy, S. R., 1353
Ellingboe, J., 309
Elliott, P. J., 1809
Elmer, G. I., 1417
Engel, J. A., 237
Eriksson, C. J. P., 1115
Erinoff, L., 1039
Erwin, V. G., 99, 949
Etscorn, F., 567
Ettenberg, A., 983
Evans, C. B., 1767
Even, P., 647

Falck, B., 1611
Fasmer, O. B., 1083, 1441
Feldon, J., 241, 1539
Ferko, A. P., 543
Fernández-Guasti, A., 673, 1065
Ferrell, F., 1695
Fertig, J. B., 159
Figueiredo, J. C., 1287
Filart, R., 931
File, S. E., 193, 525, 1465, 1467
Fish, I., 143
Fitts, D. A., 967
Fletcher, P. J., 1133
Flicker, C., 1287
Flood, J. F., 631
Frankenhaeuser, M., 1521
Franklin, K. B. J., 319
Franklin, M., 1491
Fraser, S., 1491
Fratelli, M., 991
Freedman, D. X., 407
Freedman, R., 127
Freeman, G. B., 1687
Fregly, M. J., 721
Fujiwara, M., 1715
Fukuda, T., 571, 1445
Fuller, R. W., 281
Fung, Y. K., 139
Furukawa, H., 1275
Furukawa, T., 1445
Furuno, K., 571

Gaffney, D., 665
Gage, F. H., 1611
Gardner, C. R., 1479
Garza, R. de la, 765
Geller, E. B., 1761
Gelpke, L. W., 1123
George, F. R., 1089, 1417
Gibson, G. E., 1687
Gill, K., 463
Ginn, S. R., 677
Giorlando, M., 757, 905
Gobaille, S., 657
Gordon, C. J., 1147
Goeders, N. E., 1429
Gormezano, I., 1293
Gorzalka, B. B., 1461
Gosden, B., 1491
Gosnell, B. A., 5
Gottesfeld, D. S., 757
Goudie, A. J., 1547
Gougos, A., 801
Gower, A. J., 1253
Glavin, G. B., 869, 1423
Glennon, R. A., 43
Glick, S. D., 1257
Graf, M. V., 1797
Grossi, F., 93
Grupp, L. A., 1167, 1369
Guerri, C., 1115
Gullberg, E. I., 1695
Guy, A. W., 151

Hagen, L. S., 567
Hajós, M., 889
Halperin, J. M., 875
Hamburger-Bar, R., 9
Hannan, C. J., Jr., 1141
Hara, C., 1785
Hara, T., 1423
Harding, J. W., 813
Harding, S. C., 743
Harrison, R. G., 1095
Harro, J. E., 1
Hartline, R. A., 1137
Harvey, J. A., 1293
Hata, S., 1323
Hawkins, M. F., 1195
Hennig, C. W., 1623
Henningfield, J. E., 1111
Heppner, C. C., 1555
Herberg, L. J., 193

Hernandez, D. E., 425
Herrera, E., 625
Herskovic, J. E., 171
Hilakivi, I. T., 613, 1451
Hill, J. L., 1263
Hillegaart, V., 1409
Hiramatsu, M., 1629
Hirano, H., 1423
Hirose, Y., 315
Hirst, M., 33, 561
Hjorth, S., 237
Hoffer, B., 1403
Hoffman, D. C., 259
Hole, K., 709, 1083, 1441
Horita, A., 151
Hosokawa, T., 1789
Hough, L. B., 1257
Huang, D., 205
Hunskaar, S., 709
Hunt, D., 159
Hunt, M. M., 1129
Hunt, T., 1793
Hunter, A. J., 1175
Huttunen, P., 1733

Ida, Y., 115
Iglesias, R., 1817
Imura, K., 1323
Insel, T. R., 1263
Invernizzi, R., 1189
Iorio, L. C., 875
Iredale, R. A., 247
Irwin, J., 1151
Isaac, W., 503
Itoh, Y., 571
Iwasaki, K., 1715

Jacobson, A. E., 1403
Jaffard, R., 519
James, H. E., 785
Janocko, L., 1651
Jarvik, M. E., 171, 631
Jarvis, M. F., 757
Jeppsson, B., 1611
Jhamandas, K., 1353
Johanson, C. E., 693, 765, 855, 1665
Johnson, P., 1333
Johnson, R. E., 1749
Johnson, S. W., 127
Johnston, A. L., 1467
Joly, D., 199
Jones, B. J., 1487
Jonsson, G., 975, 1397
Jørgensen, H. A., 1083
Joseph, J. A., 253
Jovanović-Mićić, D., 329
Joy, R. M., 85

Kalant, H., 93, 801
Kalhorn, T. F., 485, 491
Kalikhevich, V. N., 889
Kalverdijk, E. H., 285
Kamata, S., 1323
Kameyama, T., 1275, 1629
Kastin, A. J., 1785, 1797
Katerinopoulos, H. E., 253
Kavaliers, M., 561
Keim, K. L., 1123
Keith, A. B., 1129
Keller, E. A., 449
Keller, J., 71
Kemble, E. D., 1555
Khanna, J. M., 93, 801
Kiivet, R. A. K., 1
King, T. R., 107
Kirkpatrick, B., 1203
Kisara, K., 27
Kiyota, Y., 687, 1729
Kizer, J. S., 1269
Klemfuss, H., 229
Kleven, M. S., 341
Kline, F. S., 1305
Klukowski, G., 1793
Koja, T., 1445
Koob, G. F., 61, 1813
Kovalzon, V. M., 889
Kozak, W., 773
Krahn, D. D., 5
Krstić, S. K., 1509, 1821
Kruissink, N., 575
Kulig, B. M., 1805
Kuriyama, K., 79
Kuroda, H., 315
Kurumiya, S., 1101

Lace, J. W., 1137
Lai, H., 151
Lajtha, A., 305
Lappe, R. W., 1573
Larscheid, P., 963
Larson, A. A., 49, 347
Larsson, K., 673, 1065
Lê, A. D., 93, 801
Lebrun, C. J., 1813
Leibowitz, S. F., 911, 931, 1047
Le Petit, J., 1543
LePiane, F. G., 1577
Leprohon-Greenwood, C. E., 1775
Lerner, T., 241
Lessor, R., 1403
Levin, B. E., 299
Levin, E. D., 819
Levin, L. E., 449
Levine, A. S., 5
Lewis, M. H., 1203
Li, T.-K., 617
Lieblich, I., 1329
Liebman, J. M., 1703
Lipartiti, M., 991
Little, H., 841
Ljungberg, T., 1755
Llobera, M., 625, 1817
Lodge, D., 23
Logan, L., 1281, 1333
Long, M. D., 1147
López, D., 625
Löscher, W., 1007
Louis-Ferdinand, R. T., 211
Lozada, C., 1503
Lucot, J. B., 537
Lumeng, L., 617
Lundberg, U., 1521
Lynch, M. R., 941
Lynch, W. C., 833

McBride, W. J., 617
McCabe, J. T., 1047
McCall, R. B., 359
McCann, D. J., 187
McCloskey, T. C., 727
McCown, T. J., 1269
McDermott, J. R., 1229
McDermott, L. J., 1739
McDonough, J. H., 845
McIntyre, T. D., 895
McKenney, J. D., 43
McKenzie, G. M., 919
McLellan, C. A., 1587
McMaster, S. B., 865
McNaughton, N., 1497
Maayani, S., 127
MacDonald, C., 1639
Mackey, W. B., 71
Mailman, R. B., 1203
Maimets, M., 469
Mäkelä, J. P., 613
Malovechko, R., 1793
Mandel, P., 657
Marek, P., 791
Marks, M. J., 743, 1767
Marley, R. J., 665
Marmon, M. M., 1605
Martin, D., 23
Martin, P., 177
Martin, W. R., 393
Martin-Iverson, M. T., 1707
Mason, G. A., 425
Massotti, M., 1241
Masur, J., 1225
Matthies, H., 439
Mattingly, B. A., 1635
Matsuda, T., 1445
Matsuo, N., 1445
Mayor, R. B., 1263
Mazurkiewicz-Kwilecki, I. M., 513
Medina, M. A., 55
Meisch, R. A., 1089, 1417
Melchior, C. L., 955
Melia, K. F., 1813
Mello, N. K., 309
Mendel, V. E., 247
Mendelson, J. H., 309
Meyerson, L. R., 253
Michael, R. P., 1617
Michalak, K., 1573
Mickley, G. A., 1739
Miller, D. D., 223
Miner, L. L., 743, 1767
Misra, A. L., 761
Miyamoto, M., 687
Miyazaki, M., 79
Mizuki, Y., 1423
Modrow, H. E., 845
Mohammed, A. K., 975
Molina, V., 657
Molinengo, L., 1801
Montoya, E., 1817
Moore, G. A., 567
Moore, J. D., 1749
Moore, K. E., 795
Moore, S., 785
Mora, S., 433
Moray, L. J., 1269
Morley, J. E., 5
Morrow, E. L., 55, 949
Morseth, S. L., 813
Moss, R. L., 507, 1235
Mujica-Gonzalez, M., 715
Murdock, P., 1491
Murphy, J. M., 617
Murphy, S. D., 733, 737
Mycek, M. J., 1651
Myers, R. D., 1733
Myslobodsky, M. S., 241

Nabeshima, T., 1275, 1629
Nagaoka, A., 687, 1729
Nagasaki, N., 115
Nagawa, Y., 687
Nakajima, S., 919
Nakata, N., 27
Nance, D. M., 107
Nandedkar, A. K. N., 1383
Narula, A. P. S., 253
Narumi, S., 1729
Neville, K., 1497
Newman, M., 9
Nichols, D. E., 335
Nicolaidis, S., 647
Nielsen, J. A., 795
Nielsen, P., 1687
Nil, R., 587
Nishibori, M., 571
Nobili, O., 1543
Nobin, A., 1611
Nurk, A., 469
Nutt, D. J., 841, 1465, 1491

Obál, F., Jr., 889
Ogawa, N., 315
Ogren, S. O., 463
Oh, E. I., 1077
Oishi, R., 571
Okada, A., 1323
Okuda, C., 79
Olds, M. E., 1101
Oliveira de Souza, M. L., 1225
O'Neill, K. A., 155
Orme, A. E., 631
Orsetti, M., 1801
Orsingher, O. A., 449
Ortolani, E., 183
Ott, T., 439
Overstreet, K. H., 1593

Palazzesi, S., 183
Palfai, T., 1457
Pang, K., 127, 1403
Panocka, I., 791
Parker, K., 159
Parker, L. A., 883
Pasternak, G. W., 1721
Pastor, G., 1703
Paterson, I. A., 1487
Paul, S. M., 1673
Paule, M. G., 479, 597
Payne, A. P., 1175
Pearson, J. R., 1175
Pedersen, C. A., 1185
Pederson, M. C., 1095
Peffer, P. G., 1025
Pellow, S., 193, 525
Pendleton, N., 1461
Penetar, D. M., 111
Pennisi, G., 1393
Penke, B., 889
Perlanski, E., 1167
Peroutka, S. J., 1513
Peters, D. A. V., 1377
Pfaus, J. G., 1461
Phillips, A. G., 1577
Phillis, J. W., 263
Philpott, K., 1397
Picker, M., 555, 1583
Poling, A., 555, 1583

Pomerleau, O. F., 159
Pontani, R. B., 761
Pontecorvo, M. J., 1287
Portzline, T., 1721
Powell, D. A., 677
Prado-Alcalá, R. A., 715, 905
Prange, A. J., Jr., 425, 1185
Pranzatelli, M. R., 1679
Prince, C. R., 323
Puciłowski, O., 773
Puglisi, K., 271

Rabii, J., 757
Radke, J. M., 1707
Rae, G. A., 829
Rafferty, M. F., 417
Rägo, L. K., 1
Raigoza, V. P., 849
Ramirez, V. D., 147
Randt, C. T., 143
Rangeley, R. W., 561
Raskin, L. A., 455
Ratner, A., 67
Rauh, C. E., 253
Rauste von Wright, M., 1521
Ray, D. W., 445
Rebec, G. V., 1561
Reich, S., 1605
Reid, D., 1547
Reith, M. E. A., 305
Rennert, O. M., 1333
Repetti, S. J., 1123
Reymann, K. G., 439
Riblet, L. A., 701
Rice, K. C., 1403
Rice, M. A., 941
Riley, E. P., 165
Risner, M. E., 1071
Ritz, M. C., 1089
Roache, J. D., 1749
Robert, M., 9
Roberts, M. H. T., 1487
Robertson, A., 1639, 1793
Robinson, S. E., 941
Robinson, S. R., 165
Rockman, G. E., 869
Roda, L. G., 1031
Roderick, T. H., 1333
Rogers, L. J., 549
Roney, P. L., Jr., 737
Roscetti, G., 1031
Rose, B. B., 1315
Rose, J. E., 171
Rosen, J. B., 211
Ross, D. H., 1659
Rowan, C. H., 1761
Rowland, N. E., 721
Ruddle, J., 1605

Sacchetti, G., 991
Sadowski, B., 791
Saeki, K., 571
Sahgal, A., 1229
Saito, A., 79
Saito, K., 1789
Sakurada, S., 27
Sakurada, T., 27
Samanin, R., 1189
Samardžić, R., 329, 581, 1821
Samuels, S., 143
Sanders, D. L., 567
Sanger, D. J., 199
Sáry, G., 889
Sasaki, Y., 27
Satinder, K. P., 879
Scapagnini, U., 1185, 1393
Schechter, M. D., 769, 1161, 1209, 1533
Schenk, S., 1793
Schiffman, S. S., 429
Schindler, C. W., 1293
Schlemmer, R. F., Jr., 381
Schmitt, P., 497
Schneider, C. W., 1137
Schnur, P., 849
Schoenberger, G. A., 1797
Schouten, M. J., 1219
Schuster, C. R., 693, 855
Schuster, D. I., 253
Schwartz, S. A., 143
Seale, T. W., 1281, 1333
Sedvall, G., 1521
Seiden, L. S., 229, 537
Sellers, T. L., 605
Seyler, L. E., Jr., 159
Shannon, H. E., 1071
Shannon, N. J., 795
Sharp, T., 1755
Shatz, K., 463
Shearman, G. T., 861
Shibata, S., 1715
Shor-Posner, G., 931
Si, E. C. C., 899
Siegel, P. B., 39
Signs, S. A., 769
Simon, P., 177
Simone, D. A., 1721
Sinclair, J. D., 1451
Skolnick, P., 417, 1673
Skupny, A., 309
Slangen, J. L., 575, 999
Slattery, J. T., 485, 491
Sloan, J. W., 393
Smith, E. O., 1025
Smith, G. E., 631
Smith, J. E., 1429
Smith, L. M., 1513
Smolen, A., 1077
Smolen, T. N., 1077
Smotherman, W. P., 165
Snell, C. R., 1229
Snoddy, H. D., 281
Snodgrass, S. R., 1039, 1679
Soblosky, J. S., 1361
Sobrian, S. K., 1383
Söderberg, U., 975
Soosaar, A., 469
Soubrié, P., 177
Souza, R. L. N., 829
Sparber, S. B., 341
Spillantini, M. G., 1241
Spivak, K., 1527
Ståhle, L., 291
Stanley, D. A., 425
Stanley, M., 701
Starr, B. S., 837
Starr, M. S., 837
Stefanović-Denić, K., 581
Steiner, N. O., 503
Steinhoff, W. C., 1623
Stenfors, C., 861
Stevens, K. E., 1739
Stewart, R. B., 1167, 1369
Strek, K. S., 1147
Strickland, J. A., 135
Su, K., 1257
Sullivan, A. C., 299
Sutton, M. E., 455
Suzuki, K., 27
Swerdlow, N. R., 61
Swinyard, E. A., 1301
Szechtman, H., 1779

Tabakoff, B., 955
Tachiki, K. H., 1315
Takahashi, R. N., 829
Takeichi, T., 1101
Tanaka, M., 115, 1445
Tempel, D., 931
Terzić, B., 329
Teskey, G. C., 561
Testar, X., 625
Thiebot, M. H., 1471
Thurmond, J. B., 1361
Tiznado, E., 785
Török, A., 889
Towell, J. F., 99
Treit, D., 217
Triscari, J., 299
Trulson, 351, 445
Tsuda, A., 115
Tsujimaru, S., 115
Tsukamoto, S., 315
Tulley, R. T., 1195
Tuohy, P. A., 1175
Tveiten, L., 1441
Twery, M. J., 1203

Ueki, S., 1715
Uhlenhuth, E. H., 1665
Umemoto, M., 1101
Ungerstedt, U., 291, 1755
Uretsky, N. J., 139, 223
Ushijima, I., 115, 1423

Vaccarino, F. J., 61
Vadlamani, N. L., 761
Valentino, D., 155
Valzelli, L., 773
van Delft, A. M. L., 1253
van den Buuse, M., 15
van de Poll, N. E., 285
Van Der Gugten, J., 575
van der Kooy, D., 71
Van Krey, H. P., 39
Vasar, E., 469
Veldhuis, H. D., 15
Vellucci, S. V., 823
Venturelli, F., 1031
Verlangieri, A. J., 1567
Versteeg, D. H. G., 15
Vincent, S. R., 1707
von Wright, J., 1521

Wada, H., 1323, 1789
Wade, C. E., 1129
Wagner, G. C., 757
Waller, M. B., 617
Walser, M. M., 49
Wang, Y., 1403
Wanless, I. R., 1167
Washington, D. O., 263
Watanabe, K., 1423
Watanabe, T., 1323
Webster, R. A., 823
Wehner, J. M., 665
Weiner, G. R., 1397
Weiner, I., 1539
Weiss, F., 983
Weiss, G. K., 67
Wellman, P. J., 605, 1605
Wendt, R. L., 1573
Wenger, G. R., 479, 597
West, C. H. K., 1617
White, F. J., 365
White, W., 1583
Wichlinski, L., 1457
Wiesner, J. B., 507, 1235
Williams, F. E., 247
Wilson, C. A., 1175
Wilson, L. I., 1157
Wilson, M. C., 205, 1567
Winter, J. C., 187
Witkin, J. M., 121, 751, 963
Wolf, H. H., 1301
Wood, L. M., 1123
Woodruff, K. S., 165
Wooldridge, G. E., 879
Woolverton, W. L., 531
Worth, T., 1397
Wright, J. von, 1521
Wright, J. W., 813
Wulcko, S., 439

Yamada, K., 1445
Yamada, M., 1423
Yamaguchi, K., 1275
Yasuda, R. P., 1397
Yeh, S. Y., 925
Yehuda, S., 1775
Yelvington, D. B., 67
Yim, G. K. W., 899
Yoshida, S., 1275
Young, A. M., 211, 1305
Young, J. E., 1567

Zacharko, R. M., 1151
Zahniser, N. R., 1397
Zarkovsky, A. M., 1215
Zetterström, T., 1755
Zona, C., 1031
Zwicker, A. P., 809, 1225